| Entries |
| Document | Title | Date |
|---|
| 20080206320 | COMPOSITION COMPRISING AT LEAST ONE 15-PGDH INHIBITOR - The invention relates to a cosmetic composition containing at least one 15-hydroxy-prostaglandin dehydrogenase inhibitor and cosmetically acceptable excipients. It also relates to a method of cosmetic treatment for promoting the growth and/or preventing or delaying the loss of hair, and the use of a 15-hydroxyprostaglandin dehydrogenase inhibitor for the preparation of a composition intended for controlling hair loss and/or for promoting hair regrowth. | 08-28-2008 |
| 20080213354 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. | 09-04-2008 |
| 20080213355 | Method and System for in Vivo Drug Delivery - A system and method for polymeric drug delivery vehicles activated by ultrasound is disclosed herein. The system and method include polymeric particles, partially filled with a gas or a gas precursor, and partially filled with a liquid containing a drug. The drug is then released locally by application of ultrasound. Because the drug is dissolved, the delivery thereof is more efficient than for drugs incorporated with or in the polymeric shell of such particles. | 09-04-2008 |
| 20080213356 | Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof - The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression. | 09-04-2008 |
| 20080233184 | Combination enzyme products - The present invention provides a unique package as well as methods packaging an enzyme portion and a substance portion. The package is bifurcated to maintain an enzyme separate from a primary substance until a predetermined set of environmental conditions is met. When the environmental conditions are met, the enzyme acts as a catalyst of the primary substance facilitating a change of the primary substance into a second substance. The environmental conditions can include, for example, conditions associated with a human alimentary canal. | 09-25-2008 |
| 20080248100 | MAGNESIUM COMPOSITIONS AND USES THEREOF - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 10-09-2008 |
| 20080248101 | Pharmaceutical composition containing fenofibrate and method for the preparation thereof - A pharmaceutical composition containing fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose reduces food effect. The cellulose derivative represents less than 20 wt. % of the composition. The association of fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enhances the bioavailability of fenofibrate. Also provided is a method for preparing said composition without organic solvent. | 10-09-2008 |
| 20080254110 | Composition For Enhancing Immunity and Reducing Inflammation Related to Infections - A composition and method for enhancing immunity and reducing or inhibiting inflammation related innate immune system activation while affording the body of a user protection against known detrimental byproducts of immune-response is provided. The composition comprises at least a therapeutically effective amount of vitamin C and extract of | 10-16-2008 |
| 20080260813 | PHARMACEUTICAL COMPOSITION OF TOPIRAMATE - The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described. | 10-23-2008 |
| 20080268034 | Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide - The present invention relates to solid oral dosage forms of ziprasidone and salts thereof and processes for their preparation, containing colloidal silicon dioxide. | 10-30-2008 |
| 20080268035 | Cationic Polymer Nanoparticles Encapsulating An Active Ingredients, And The Cosmetic Composition Containing The Same - Disclosed herein are cationic polymer nanocapsules encapsulating an oil-soluble active ingredient, and a cosmetic composition containing the same. The cationic polymer nanocapsules have a molecular weight of 5,000-100,000, a surface potential of 5-100 mV and a particle size of 50-500 nm. Also, disclosed is a cosmetic composition containing said cationic polymer nanocapsules. | 10-30-2008 |
| 20080268036 | Co-processing of active pharmaceutical/nutraceutical ingredients - A process for preparing agglomerated particles comprising a) preparing a slurry of a pre-manufactured agglomerated particles consisting of microcrystalline cellulose and one or more compressibility augmenting agents, and an active ingredient; and b) drying the slurry to form active agent agglomerated particles. | 10-30-2008 |
| 20080286354 | COMPOSITION AND THERAPIES FOR HYPERLIPIDAEMIA-ASSOCIATED DISORDERS - The invention relates to pharmaceutical compositions comprising at least one fibrate and at least one bile acid, and to methods for the treatment of hyperlipidaemia or elevated liver function tests in a patient by administering at least one fibrate and at least one bile acid to the patient. | 11-20-2008 |
| 20080292690 | MULTI-MEMBRANE IMMUNOISOLATION SYSTEM FOR CELLULAR TRANSPLANT - This invention relates to an immunoisolation encapsulation system that protects cellular transplants and thus allows cell function and survival without the need of immunosuppression. The immunoisolation system is a multi-component, multi-membrane capsule that allows optimization of multiple design parameters independently for reproducible functions in large animals models. | 11-27-2008 |
| 20080292691 | BARIATRIC MAGNETIC APPARATUS AND METHOD OF MANUFACTURING THEREOF - A bariatric procedure or delivery apparatus is configured in such a way to deter premature passing of magnetic members through the pylorus. In other exemplary embodiments, the magnetic apparatus includes a plurality of magnetic members, having one of a variety of configurations, wherein plural magnetic poles are disposed on a surface of the apparatus. | 11-27-2008 |
| 20080299185 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 12-04-2008 |
| 20080299186 | COATINGS FOR APPLYING SUBSTANCES ONTO SUBSTRATE CARRIER - Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises polyvinyl alcohol or a polyvinyl alcohol derived copolymer. | 12-04-2008 |
| 20080305158 | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine - The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation. | 12-11-2008 |
| 20080311186 | Composition Having Effect on Treatment and Prevention of Dry Eye Syndrome - Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the present invention is effective in the treatment and prevention of dry eye syndrome. | 12-18-2008 |
| 20080317841 | Pharmaceutical Composition Containing Coated, Floating Particles - A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating. | 12-25-2008 |
| 20080317842 | Fast Wet-Massing Method for the Preparation of Calcium-Containing Compositions - The present invention relates to a novel process for the preparation of a granulate comprising a calcium-containing compound as an active substance. The method comprises a method for the preparation of a granulate comprising a calcium-containing compound as an active substance, the method comprising, i) feeding a granulation chamber with a composition comprising the calcium-containing compound, ii) wet-massing the composition with a granulation liquid optionally comprising a pharmaceutically acceptable binder for a time period of at the most 30 sec to obtain a wet granulate, iii) drying the thus obtained wet granulate. A granulate obtained by the present method is especially suitable in the preparation of solid dosage forms, in particular in the preparation of tablets. | 12-25-2008 |
| 20090011006 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 01-08-2009 |
| 20090011007 | Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water - The invention relates to a pharmaceutical composition comprising a mixture of at least one cationic, water-soluble (meth)acrylate copolymer, at least one water-insoluble polymer and at least one active ingredient having a solubility in demineralized water of 3.3 g/l or less, characterized in that the water-insoluble polymer and the active ingredient are present in a ratio of at most 3.5 to 1 parts by weight, and the pharmaceutical composition has the property of releasing the active ingredient present in a medium buffered to pH 1.2 in dissolved form in a concentration which, after 2 hours at pH 1.2, corresponds to at least sixteen times the solubility value of the active ingredient alone at pH 1.2. | 01-08-2009 |
| 20090011008 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 01-08-2009 |
| 20090017109 | METHOD OF REDUCING SOMNOLENCE IN PATIENTS TREATED WITH TIZANIDINE - An article and method for reducing somnolence in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release multiparticulate composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 01-15-2009 |
| 20090017110 | MODIFIED RELEASE FORMULATIONS OF ANTI-IRRITABILITY DRUGS - Modified or extended release formulations containing mesalamine compounds and associated methods are disclosed and described. In some aspects, such formulations may be substantially bioequivalent to known FDA approved mesalamine formulations such as PENTASA®. | 01-15-2009 |
| 20090022785 | Permeable Capsules - The present invention relates to permeable capsules comprising at least one cell comprising a recombinant nucleic acid molecule with a heat inducible promoter operably linked to a nucleic acid encoding for a protein, a peptide or a functional nucleic acid molecule and at least one heat emitting agent capable to emit heat when exposed to electromagnetic radiation or to a magnetic field. | 01-22-2009 |
| 20090022786 | Oral pharmaceutical dosage form and manufacturing method thereof - The present invention provides an coated oral pharmaceutical dosage form comprising a composition of a non-steroidal anti-inflammatory drug (NSAID) as multilayered spherical granule combined with a composition of prostaglandin, and a film coating. The present invention also provides a method for manufacturing the dosage form, which comprising the steps of preparing the compositions of NSAID and prostaglandin separately, combing the compositions to form a pharmaceutical dosage form, and coating the dosage form with a film coating. | 01-22-2009 |
| 20090028934 | GRANULAR, GASTRO-RESISTANT PRODUCT BASED ON NIACIN OR DERIVATES THEREOF AND PROCESS FOR THE PRODUCTION OF SUCH A PRODUCT - A granular, gastro-resistant product based on niacin or derivatives thereof comprises an internal part in which the niacin is substantially concentrated and an external coating, provided to cover and protect the internal part, made up of a matrix having a total weight fraction of long-chain C16-C22 saturated fatty acids of between 40% and 95% relative to the matrix. A process for the production of such a granular product is also described. | 01-29-2009 |
| 20090035365 | Density Controlled Capsule Particles and Methods of Making the Same - The present invention discloses density controlled capsule particle and methods for making the same for use in a wide range of consumer and personal care products. | 02-05-2009 |
| 20090035366 | Nanoparticulate benzothiophene formulations - The present invention is directed to benzothiophene compositions, preferably nanoparticulate raloxifene hydrochloride compositions having improved pharmacokinetic profiles, improved bioavailability, dissolution rates and efficacy. In one embodiment, the raloxifene hydrochloride nanoparticulate composition have an effective average particle size of less than about 2000 nm. | 02-05-2009 |
| 20090053303 | MEDICAL FOOD OR NUTRITIONAL SUPPLEMENT, METHOD OF MANUFACTURING SAME, AND METHOD OF MANAGING DIABETES - A medical food and/or nutritional supplement for oral administration by mammals includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacturing the medical food or nutritional supplement is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid. | 02-26-2009 |
| 20090053304 | Composition and method of producing a taste masking formulation of laxatives for bowel cleaning preparation prior to colonoscopy - This invention relates to a solid taste masking formulation of laxatives which can be dispersed in water for oral use for bowel cleaning preparation prior to colonoscopy procedures. This invention also relates to the methods to produce the taste masking laxative formulations. | 02-26-2009 |
| 20090068259 | Controlled Surface Gelling of Mucoadhesive Polymers on Oral Mucosa - The present invention relates to an oral composition and method for alleviating the symptoms associated with xerostomia using encapsulated cation-releasing compounds formulated either intimately together or in separate compartments in a composition containing cation-sensitive mucoadhesive polymers. | 03-12-2009 |
| 20090074854 | COMBINED-STEP PROCESS FOR PHARMACEUTICAL COMPOSITIONS - The invention relates to a process for the solid oral pharmaceutical formulation of a pharmaceutically active ingredient such as levetiracetam, comprising a wet granulation of the pharmaceutically active ingredient and simultaneous fluid bed drying such that, as the pharmaceutical blend granulates it is simultaneously dried thus preventing it from becoming a paste. The invention therein thus provides a novel formulation preparation process characterized by a “combined” Granulation and Fluid Bed Drying process step. | 03-19-2009 |
| 20090081285 | USE OF RADICAL-CAPTURING SUBSTANCES IN A TOPICAL PREPARATION FOR ANTIPYRETIC TREATMENT - The present invention relates to the use of one or more radical-capturing substances as therapeutically active substances in a topical preparation for antipyretic treatment. The invention is also directed to the use of radical-capturing substances as active agents in a combined preparation for the treatment of fever, said combined preparation comprising a topical preparation and an oral preparation in free combination, and the two preparations independently including one or more free-radical-capturing substances. | 03-26-2009 |
| 20090087483 | ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING - Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module. In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a three piece capsule, a capsule-in-a-capsule or a tablet-in-a-capsule, and the primary and secondary modules are interchangeable. | 04-02-2009 |
| 20090098198 | Satiety - A capsule for suppressing appetite, comprising:
| 04-16-2009 |
| 20090098199 | METHODS OF TREATING GASTROINTESTINAL DISORDERS INDEPENDENT OF THE INTAKE OF FOOD - The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food. | 04-16-2009 |
| 20090110721 | Paneled capsule shells for release of pharmaceutical compositions - Capsule shells for use in multi-part dosage forms have generally cylindrical shell members with a snap fit component on an interior surface adjacent an open end, for connection to a linker part of the dosage form. The shell member also has a plurality of spaced apart integrally formed thin (relative to circumferentially adjacent shell member portions) panels located adjacent a closed shell member end, for preferential dissolution and release of pharmaceutical compositions from the shell member interior. The ratio of the thickness of the panels to the thickness of the shell member ranges from about 0.2 to about 0.6. The panels can be integrally formed together with the shell member as reliefs or depressions on the inner surface of the shell member by injection molding, and panel thicknesses as thin as about 0.1 mm can be achieved, | 04-30-2009 |
| 20090123534 | Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof - The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame seed oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion. | 05-14-2009 |
| 20090130196 | Bacteriophage composition - Bacteriophage compositions, and methods for preparing bacteriophage compositions are provided. The method for producing an antibacterial composition involves adsorbing an aqueous solution of one or more bacteriophages, or one or more phage components, onto a matrix to produce a composition, and drying the composition to produce the antibacterial composition. An antibacterial composition comprising one or more strain of bacteriophage, or one or more phage component, adsorbed onto a matrix is also provided. The antibacterial composition may also be encapsulated. The antibacterial composition, or the encapsulated antibacterial composition, may be used within a cream, lotion or gel, be admixed with a pharmaceutical carrier and administered topically, orally, nasally, used as a powdered inhalant, or the antibacterial composition or encapsulated antibacterial composition, may be added to a feed for animal, aquatic or avian uses. | 05-21-2009 |
| 20090148512 | NOVEL USES OF CHLORAMPHENICOL AND ANALOGOUS THEREOF - A method for reducing the resistance of an MRSA bacterium to an antibiotic selected from the group consisting of vancomycin and methicillin comprising administering to a patient in need thereof an effective amount of chloramphenicol or analogues thereof. The invention is also directed to chloramphenicol containing pharmaceutical compositions. | 06-11-2009 |
| 20090148513 | Compositions and methods for crystallizing antibodies - The present invention relates to a batch crystallization method for crystallizing anti-human TNFalpha (hTNFalpha) antibody and antibody fragments which allows the production of said antibody on an industrial scale; a method of controlling the size of antibody crystals, for example, crystals of anti-hTNFalpha antibody fragments, compositions containing said crystals as well as methods of use of said crystals and compositions. | 06-11-2009 |
| 20090148514 | Multipart capsule for staged release of one or more pharmaceutical compositions - A multipart capsule, e.g., a dosage form, is provided which includes a plurality of capsule portions, at least one of which contains a substance to be released into a gastro-intestinal environment and at least one link component interconnecting two adjacent capsule portions. At least one capsule portion is formed from a polymer that is a transitional polymer, for example, a polymer that changes shape, form, or structure within a gastro-intestinal environment, e.g., dispersible, dissolvable, disintegrable, fracturable, breachable, swellable, partially or completely soluble, or otherwise changeable when exposed to stomach pH and/or in intestine pH to thereby release the substance. The capsule portions are connected together in an assembled dosage form. The link component includes at least one aperture in flow communication with interiors of two adjacent capsule portions to control the release of the substance. | 06-11-2009 |
| 20090148515 | TWO-PIECE METAL CAPSULE FOR ACCOMMODATING PHARMACEUTICAL PREPARATIONS FOR POWDER INHALERS - The invention relates to novel two-piece metal capsules for accommodating pharmaceutical preparations to be used in powder inhalers as well as a method for producing said capsule. The inventive capsules are particularly impermeable to steam and oxygen. | 06-11-2009 |
| 20090155351 | Solid Vaccine Formulation - The invention relates to a solid vaccine formulation adapted for mucosal administration comprising at least one antigen as active substance, wherein the formulation comprises a lyophilisate of a suspension comprising an oxygen-containing metal salt, the antigen(s) and one or more excipients selected from (i) saccharides, (ii) sugar alcohols, and (iii) amino acids or pharmaceutically acceptable salts thereof. | 06-18-2009 |
| 20090155352 | Microemulsion containing indolocarbazole compound and dosage forms containing the same - The invention described herein provides a pharmaceutical composition and oral dosage forms containing the same, having high concentrations of solubilized indolocarbazole compounds as the active ingredient in microemulsion form. The invention also provides a process for increasing the solubilized concentration of indolocarbazole compounds such as lestaurtinib using the addition of water in combination with a hydrophilic component as part of the microemulsion formation process. | 06-18-2009 |
| 20090155353 | MICROEMULSIONS FOR PHARMACEUTICAL COMPOSITIONS - The invention provides microemulsion pharmaceutical compositions comprising pharmaceutical actives which are hydrotropes that facilitate formation of microemulsions. The invention further provides methods of making the compositions and utilization of the compositions in liquid fill soft shell capsules including capsules having shells of non-animal derived materials (e.g. non-ADRM). | 06-18-2009 |
| 20090162428 | Immediate disintegration polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof - An immediate disintegrating polymeric matrix for oral administration with modified release is disclosed, obtained without using inert supports such as sugar spheres, comprising particles of active substance directly covered with a release regulating membrane. Use of such a matrix to prepare various administration forms for oral use as well as the method of its preparation are also disclosed. | 06-25-2009 |
| 20090186080 | METHODOLOGY AND APPARATUS FOR ORAL DUAL DELIVERY OF HOMEOPATHIC PRODUCTS AND NON-HOMEOPATHIC PRODUCTS - One possible embodiment of the invention may be an oral dosage apparatus comprising of a sealed, digestible container having an exterior that defines and seals a respective interior; the interior containing one or more non-homeopathic remedies; and the exterior presenting one or more homeopathic products. Another version of the invention may be a method of manufacturing an oral dosage apparatus comprising of the following steps of providing one or more non-homeopathic remedies and one or more non-homeopathic remedies; providing a sealed, digestible container having an exterior that correspondingly defines and seals a respective interior containing one or one or more non-homeopathic remedies; affixing one or more homeopathic remedies to the exterior. | 07-23-2009 |
| 20090202628 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one protein drug or bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular protein drug and bioactive agent delivery. | 08-13-2009 |
| 20090208566 | Capsules Containing Seminal Material for Artificial Insemination - Capsules or microcapsules comprising: a) a nucleus containing seminal material or the spermatozoa of animal species chosen from the group consisting of equids, buffalo, ovicaprids, canids, felids, lagomorphs, laboratory animal species chosen from mice and rats, and possibly man, b) a membrane of a bivalent or trivalent metal alginate. | 08-20-2009 |
| 20090208567 | SUBSTANCE-CONTAINING CARBON NANOHORN COMPOSITE HAVING POLYAMINE PLUG AND PROCESS FOR PRODUCING THE SAME - The present invention provides: a carbon nanohorn composite including a carbon nanohorn, a substance encapsulated in the carbon nanohorn, and a polyamine adsorbed by chemical reaction firmly to a surface functional group present on the opening part on the surface of the carbon nanohorn, wherein the release amount and release rate of the encapsulated substance can be controlled using the difference in size, substituent or three-dimensional structure of the polyamine, which is used as a plug; a method of controlling the release of the encapsulated substance; and a process for producing the carbon nanohorn composite. The release amount and release rate of the substance encapsulated in the carbon nanohorn composite is controlled by selecting a polyamine molecule, which plugs the opening part formed in the carbon nanohorn by oxidation, by its size, substituent or three-dimensional structure. | 08-20-2009 |
| 20090246274 | PHARMACEUTICAL COMPOSITION 271 - The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions. | 10-01-2009 |
| 20090263475 | DEXLANSOPRAZOLE COMPOSITIONS - Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease. | 10-22-2009 |
| 20090285885 | Method of forming a drug nanocarrier having a magnetic shell - The invention discloses the synthesis and manufacturing of a novel core-shell nano-carrier with a drug-containing nanocomposite core surrounding with a single crystalline magnetic iron oxide shell. With a unique core-shell configuration, active agents such as drugs and biomolecules encapsulated in the core with an outer single-crystalline thin iron oxide shell can be perfectly protected from environmental damages and in the meantime, eliminating un-desirable release due to un-controllable diffusion of the active molecules from the nanocapsules during the course of delivery in patient's body, before reaching the disease sites. | 11-19-2009 |
| 20090285886 | ENHANCED ANTIMICROBIAL ACTIVITY OF PLANT ESSENTIAL OILS - Antimicrobial compositions based on a combination of plant essential oils of enhanced antimicrobial effectiveness are prepared by adding to the combination of at least two plant essential oils, a small but antimicrobial enhancing effective amount of an enhancer selected from the group consisting of polyionic organic enhancers and polyionic inorganic enhancers. One preferred composition it is a mixture of plant essential oils wherein at least one of the oils is oregano oil. | 11-19-2009 |
| 20090297594 | Oral Pharmaceutical Dosage Forms Comprising a Proton Pump Inhibitor and a NSAID - An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment. | 12-03-2009 |
| 20090297595 | Method For Producing A Cross-Linked Substance, Especially In The Form Of A Microcapsule Or Layer - A device for producing a crosslinked substance, e.g., of crosslinked microcapsules ( | 12-03-2009 |
| 20090304784 | SEAMLESS CAPSULES CONTAINING HIGH AMOUNTS OF POLYUNSATURATED FATTY ACIDS AND A FLAVOURING COMPONENT - A seamless capsule includes a core and a shell, wherein the core includes at least one polyunsaturated fatty acid, and at least one flavouring component, the process for manufacturing the capsule and products containing the capsule are also disclosed. | 12-10-2009 |
| 20090304785 | ESCALATING DOSING REGIMEN FOR EFFECTING WEIGHT LOSS AND TREATING OBESITY - The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions. | 12-10-2009 |
| 20090317459 | Material - There is provided a granular material comprising (i) at least 50% by weight based on the weight of the granular material of solid water-insoluble mixed metal compound capable of binding phosphate of formula (I): M | 12-24-2009 |
| 20090324710 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 12-31-2009 |
| 20100008982 | NON-COVALENT COMPLEXES OF BIOACTIVE AGENTS WITH STARCH FOR ORAL DELIVERY - The present invention relates to particles comprising non-covalent complexes which comprise starch and an active agent and dry compositions containing such particles for the oral delivery of the active agents. Preferably the particles are degraded and release the active agent within the intestines, protecting the active agent from degradation in the stomach. The present invention further relates to methods for preparing suspensions of these particles having a uniform particle size in the range of several microns. | 01-14-2010 |
| 20100015219 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULT TO IMPROPERLY DIVERT FROM THEIR INTENDED ROUTE OF ADMINISTRATION - A solid pharmaceutical composition in the form of a gel capsule containing at least one active ingredient and also at least one gelling agent chosen from cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylmethylcellulose, sodium carboxymethylcellulose (CMC) and calcium carboxymethylcellulose, and at least one disintegrating agent, the gelling agent and the disintegrating agent being present in a ratio by weight of 0.3 to 0.7/1 and the content by weight of gelling agent(s) being from 10% to 20% of the composition, and method for preparing same. | 01-21-2010 |
| 20100021534 | INJECTION-MOLDED WATER SOLUBLE CONTAINER - A rigid, water-soluble container is made of an injection molded poly(vinyl alcohol) and/or a cellulose ether, which container encases a fabric care, surface care or dishwashing composition; and a capsule container comprising at least two components made of one or more material(s) that can be molded and which are water soluble or water dispersible or in which a substantial part of the surface of these components is water soluble or water dispersible so as to leave perforations throughout the wall when the capsular container is placed in contact with an aqueous environment. The container has one to six compartments, preferably one, two or three, the content of the various compartments being accessible to the aqueous environment when the capsular container is exposed to such an aqueous environment. The accessibility time of the various compartments is the same or different from one compartment to another compartment, with the proviso that the content of the container is not a fabric care, surface care or dishwashing composition. | 01-28-2010 |
| 20100021535 | LIGHT-STABILIZED SOFT CAPSULE FORMULATIONS - An object of the present invention is to provide a small-sized light-stabilized soft capsule formulation, which has a shell that ensures effective light shielding of an active ingredient encapsulated thereby. | 01-28-2010 |
| 20100028420 | CONTROLLED RELEASE COMPOSITION AND PROCESS - A composition for encapsulation and controlled release comprises a water-insoluble matrix comprising a host molecule that is non-covalently crosslinked by multi-valent cations, that is non-polymeric, that has more than one carboxy functional group, that has at least partial aromatic or heteroaromatic character, and that comprises at least one pterin or 5-substituted pterin moiety. The composition can further comprise a guest molecule (for example, a drug) that can be encapsulated within the matrix and subsequently released. | 02-04-2010 |
| 20100047337 | PHARMACEUTICAL SPHEROIDS - According to the invention glyceryl monostearate and a polymeric binder are employed as a spheronising aid in the manufacture of pharmaceutical spheroids containing no or substantially no microcrystalline cellulose. The spheroids can contain one or more therapeutically active agent which undergoes no or substantially no degradation when stored under accelerated temperature and humidity conditions. A coating may be applied to the spheroids; when present, the coating is preferably a controlled release coating. | 02-25-2010 |
| 20100047338 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity - Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines. The compounds are potent inhibitors of human CYP17 enzyme as well as potent antagonists of both wild type and mutant androgen receptors (AR). The compounds are useful for the treatment of human prostate cancer. | 02-25-2010 |
| 20100055170 | METAL CORE NANOCAPSULES - Techniques for preparing nanocapsules are provided. | 03-04-2010 |
| 20100055171 | Pharmaceutical Formulation Comprising Donepezil - The present invention relates to a pharmaceutical composition comprising 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1H-inden-1-one, herein after referred to as Donepezil, or a pharmaceutically acceptable salt thereof, for treating of Alzheimer's disease and senile dementia. The present invention also relates to a manufacturing process for the preparation of Donepezil tablets containing and retaining polymorphic Form I of Donepezil hydrochloride. This composition also discloses the use of the excipients that ensure adequate flowability of a dry blend as well as required content uniformity and drug release rate of the final product. | 03-04-2010 |
| 20100055172 | ENCAPSULATED SOY EXTRACTS AND PROCESS FOR PREPARING SAME - Soy extracts encapsulated with oligosaccharides and processes for making the encapsulated soy extracts. The processes generally comprise combining a soy extract solution and an oligosaccharide solution to encapsulate the soy extract with the oligosaccharide, precipitation of the encapsulated soy extract solution to form sediment, centrifugation, ion exchange to remove ionic components and drying. Soy extracts encapsulated in the process include isoflavone derivatives, such as daidzin, glycitin, genistin, daidzein, glycitein and genistein, which may be encapsulated with αr-cyclodextrin, β-cyclodextrin, γ-cyclodextrin or combinations of these oligosaccharides. | 03-04-2010 |
| 20100062056 | ENCAPSULATED PICOPLATIN - The invention provides an encapsulated unit dosage form for picoplatin that is adapted for oral administration of the picoplatin containing a substantially dry powder with about 20 to 55 wt % picoplatin in the physical form of a picoplatin particulate wherein an average picoplatin particle diameter is less than about 10 microns. The picoplatin particles are dispersed within the powder of the formulation which includes a substantially water-soluble, water-dispersible, or water-absorbing carbohydrate and an effective amount of up to about 5 wt % of a lubricant. | 03-11-2010 |
| 20100086586 | Pharmaceutical Composition - A pharmaceutical composition comprising eplerenone having a D90 particle size of between 15-25 microns and further comprising one or more pharmaceutically acceptable excipients. | 04-08-2010 |
| 20100098754 | PROCESSING OF HEAT-SENSITIVE ACTIVE AGENTS - The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T | 04-22-2010 |
| 20100112044 | METHOD AND APPARATUS FOR ENCAPSULATING PHARMACEUTICAL AND NUTRICEUTICAL BIOACTIVES FOR INTESTINAL DELIVERY - A method for the encapsulation and subsequent delivery of a biologically, water or lipid soluble, active agent to the human intestinal mucosa. This biochemical pathway to drug delivery includes the steps of forming an aqueous emulsion of the pharmacological or nutriceutical agent, vegetable oil, gum and/or gum resin, absorbent factors, and a sugar; then converting the emulsion into a dry spherical particulate form, having lost its aqueous component; and then drying the resultant particulate to form acid and water insoluble intestinal absorbent biologically active beadlets. | 05-06-2010 |
| 20100119596 | FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME - The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution. | 05-13-2010 |
| 20100129439 | Adjuvant Incorporation in Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 05-27-2010 |
| 20100129440 | EMBRYONIC-LIKE STEM CELLS DERIVED FROM ADULT HUMAN PERIPHERAL BLOOD AND METHODS OF USE - The present invention is related generally to embryonic-like stem cells isolated from adult human peripheral blood, designated herein as peripheral blood-stem cells (PB-SC), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to other types of cells. These cells are, therefore, suitable for use in stem cell-based therapies, particularly autologous stem cell therapies, for the treatment of various diseases such as neurodegenerative diseases, autoimmune diseases, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects. | 05-27-2010 |
| 20100129441 | Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa - The present invention relates to stable pharmaceutical compositions comprising entacapone, levodopa and carbidopa, or pharmaceutically acceptable salts or hydrates thereof. The invention also relates to processes for the preparation of such compositions. | 05-27-2010 |
| 20100136102 | TERPENE-CONTAINING COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The present invention relates to compositions comprising terpenes and hollow glucan particles or cell wall particles and methods for preparing such compositions. The compositions increase terpene stability and activity and provide a suitable carrier for the terpenes. The invention also relates to methods of using such compositions,in the medical, veterinary and agricultural fields. | 06-03-2010 |
| 20100136103 | COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS - The invention is directed to an anti ageing skin care composition, more in particular a cosmetic anti aging skin care composition. The anti ageing skin care composition of the invention comprise, in a physiologically acceptable medium, (i) at least one peptide from Laminin-1 that is able to promote synthesis of Laminin-5; (ii) at least one peptide capable of at least partially inhibiting neuronal exocytosis; and (iii) at least one tripeptide producing a rapid and strong stimulation of collagen synthesis. The compositions of the present invention are effective in reducing existing wrinkles and/or preventing the formation of new wrinkles. | 06-03-2010 |
| 20100151009 | FORMULATIONS FOR DELIVERING INSULIN - Oral insulin formulations and processes for preparing oral insulin formulations are provided. | 06-17-2010 |
| 20100158996 | ESTER COMPOUND AND MEDICAL USE THEREOF - A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1″) | 06-24-2010 |
| 20100166850 | EPROSARTAN MESYLATE CRYSTALLINE PARTICLES AND A PROCESS FOR PREPARING PURE EPROSARTAN - The present invention relates to eprosartan mesylate particles having relatively larger surface area, to the methods for the manufacture of said crystalline particles, and to pharmaceutical compositions comprising said crystalline particles. The present invention further relates to crystalline solid of eprosartan acetate, to a process for its preparation and to a pharmaceutical composition comprising it. The present invention also provides substantially pure eprosartan free base and process for its preparation. | 07-01-2010 |
| 20100166851 | Composition having lipolytic activity, production method thereof and use of the composition - The invention relates to a composition having lipolytic activity that comprises at least polyphenols, especially in the form of flavonoids, in particular flavanones and anthocyanins, and phenolic acids, and caffeine. The invention also relates to a process for obtaining such a composition and the use of the composition for its administration with a view to promoting the burning of fats or promoting the loss of body mass. | 07-01-2010 |
| 20100166852 | Cream gels comprising at least one retinoid and benzoyl peroxide - The invention relates to a composition in the form of a cream gel comprising, in a physiologically acceptable medium, at least one dispersed retinoid and dispersed benzoyl peroxide, to its process of preparation and to its use in cosmetics and in dermatology. | 07-01-2010 |
| 20100172968 | CHIMERIC CANNULAE PROTEINS AND METHODS FOR MAKING AND USING THEM - A polymer is prepared by self-assembly of a plurality of monomeric polypeptide units. The polymer tends to form a nanotube and is capable of encapsulating a particular drug molecule. Once encapsulated in the polymer of the present invention, the drug molecule may be delivered to a particular location of human body to effectively cure a disease or treat a symptom. | 07-08-2010 |
| 20100172969 | HOT-MELT MICROPELLETS - The present invention provides a method of making solid micropellets of which at least 75% by weight have a diameter less than 500 μm comprising (i) melting one or more binders; and (ii) combining the one or more binders melted in step (i) with a pharmaceutically active ingredient to form solid micropellets. Solid micropellets obtainable by this method are also provided. The invention has particular utility for improving the solubility of poorly water-soluble pharmaceutically active ingredients. | 07-08-2010 |
| 20100172970 | ANTIVIRAL COMPOSITIONS - The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture. | 07-08-2010 |
| 20100178331 | PREPARATION FOR TRANSNASAL APPLICATION - Disclosed is a preparation for transnasal application, which has improved fluidability. Specifically disclosed is a preparation for transnasal application, which comprises at least a complex comprising: a fluidability-improving component comprising a first crystalline cellulose (A) having specified powder properties, tricalcium phosphate (B) having specified powder properties, and a second crystalline cellulose (C) having specified powder properties or a starch (D) having specified powder properties; and a physiologically active substance. | 07-15-2010 |
| 20100178332 | CELLULOSE-BASED FINE CORE PARTICLE AND PROCESS FOR PRODUCING THE SAME - It is an object of the present invention to provide a fine core particle, which comprises a coating layer having a uniform thickness, and which can be used to produce, at a high yield, a small granule causing no sandy feeling in the oral cavity when the fine core particle is applied to a fine granule or an orally-disintegrating tablet. According to the present invention, there is provided a core particle, which comprises 50% by mass or more of microcrystalline cellulose, and which has a mean particle diameter of less than 100 μm, a relative flow index of 7.0 to 30.0, a specific surface area of less than 0.15 m | 07-15-2010 |
| 20100189779 | IN VIVO DEVICE, SYSTEM AND USAGE THEREOF - An in vivo device ( | 07-29-2010 |
| 20100196462 | Method for Manufacturing a Pharmaceutical Form of Oseltamivir Phosphate - The invention relates to a method for manufacturing a pharmaceutical form of oseltamivir phosphate, characterized by including the following steps:
| 08-05-2010 |
| 20100196463 | METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 08-05-2010 |
| 20100196464 | ORLISTAT PHARMACEUTICAL FORMULATIONS - Solid pharmaceutical formulations are prepared using compositions comprising orlistat and having average particle sizes less than about 250 μm. | 08-05-2010 |
| 20100203117 | ANTI-ADIPOGENIC COMPOSITIONS CONTAINING PIPER BETLE AND DOLICHOS BIFLORUS - Herbal compositions are useful for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. The herbal compositions comprise biologically effective amounts of extracts or fractions from | 08-12-2010 |
| 20100203118 | COLLAPSIBLE WATER-CONTAINING CAPSULES - Collapsible water-containing capsules comprising by weight: (a) from about 40% to about 95% of a water phase the water phase comprising at least 50% water by weight of the water phase; and (b) from about 5% to about 20% of a spindle-shaped metal oxide powder which is hydrophobically surface-treated and has an average long axis particle size of from about 25 nm to about 150 nm, an average short axis particle size of from about 4 nm to about 50 nm, and an aspect ratio of greater than about 3. | 08-12-2010 |
| 20100203119 | PHARMACEUTICAL TREATMENT PROCESS USING CHITOSAN OR DERIVATIVE THEREOF - The present invention provides a solid composition for oral administration comprising:
| 08-12-2010 |
| 20100215732 | INGESTIBLE IMPLEMENT FOR WEIGHT CONTROL - An orally administrable implement for expanding in a stomach of an animal, including a mammal, to fill a space in the stomach, is provided for weight control. The implement includes: a fluid-permeable expandable container having a first dimension and a second dimension; and a plurality of clusters comprising a swellable material contained within the container and capable of swelling when contacted with a fluid; whereby when the implement is ingested, the fluid in the stomach enters the container causing the clusters therein to swell and the container to expand from the first dimension to the second dimension. | 08-26-2010 |
| 20100215733 | DEVICE AND METHOD FOR REDUCING CALORIE INTAKE - Devices and methods for substantially reducing the caloric efficiency of the digestive tract by capturing food being digested in the stomach | 08-26-2010 |
| 20100215734 | PHARMACEUTICAL COMPOSITIONS - The present invention provides a pharmaceutical composition in solid form comprising a poorly water soluble drug, a solubilizing component, and a surfactant which is semisolid or solid. The poorly soluble drug may e.g. be a cyclosporin or a macrolide. | 08-26-2010 |
| 20100221320 | Active Targeting Polymer Micelle Encapsulating Drug, and Pharmaceutical Composition - The present invention provides an active targeting polymer micelle encapsulating a drug, preventing an inappropriate release of a drug which may damage a normal cell. A polymer micelle | 09-02-2010 |
| 20100221321 | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions - A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of ingestion, consumption, or the like. Benefits of the present invention include maintaining separation of distinct ingredients within a single capsule and the capability to control the time release of multiple ingredients within the capsule. | 09-02-2010 |
| 20100226976 | ENCAPSULATED MESENCHYMAL STEM CELLS AND USES THEREOF - Provided is a composition-of-matter comprising a microcapsule encapsulating mesenchymal stem cells, wherein at least 97% of cells in said microcapsule are said mesenchymal stem cells. Also provided are methods of generating and using the composition-of-matter. | 09-09-2010 |
| 20100233252 | Low-Moisture-Content Hard Capsule and Production Method Therefor - A method is provided for the production of hard capsules having a low moisture content and low hygroscopicity, as well as a method for reducing the moisture content and hygroscopicity of hard capsules produced by a gel cooling process using, as principal components, a water-soluble cellulose compound and a gelling agent. The hard capsules have a water-soluble cellulose compound, gelling agent, and, if necessary, a gelling aid that has loss on drying, after 10 days of storage at 25° C. and a relative humidity of 53%, of less than 6% by weight. Such a hard capsule can be produced by heating a gelled capsule film to 50-150° C. before, after, or simultaneously with a drying step after a gelling step in a gel-cooling process for producing a hard capsule having a water-soluble cellulose compound and a gelling agent as principal components. | 09-16-2010 |
| 20100233253 | EXTENDED RELEASE GASTRO-RETENTIVE ORAL DRUG DELIVERY SYSTEM FOR VALSARTAN - An extended release gastro-retentive drug delivery system of Valsartan. The drug delivery system contains a release portion containing the Valsartan, a gastro-retentive portion for retaining the drug delivery system in the stomach and an optional secondary portion for delivering a secondary pulse of Valsartan. In another embodiment, there is provided a swellable unfolding membrane comprising Valsartan for sustained administration of Valsartan to the upper GI tract of a patient. | 09-16-2010 |
| 20100233254 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING THE SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 09-16-2010 |
| 20100239658 | GALLIUM NITRATE FORMULATIONS - The present invention relates to stable pharmaceutical formulations that include a delivery agent and/or pharmaceutically acceptable salt thereof. | 09-23-2010 |
| 20100239659 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS - The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells. | 09-23-2010 |
| 20100239660 | PRODUCT AND USE OF OMEGA-3S MATCHING HUMAN TISSUE RATIOS FOR TREATMENT OF INFLAMMATORY AND OTHER CONDITIONS - The present invention relates to a product and method for delivering of DHA and EPA in need of omega-3 treatment. It involves administering a liquid formulation such as an oil containing DHA and EPA in a ratio that closely resembles the ratio of DHA and EPA in the human body. The result is a composition that performs as good or better than fish based compositions containing omega-3 fatty acids and can be dosed into smaller volumes when administering mega doses of 1000-2000 mg of DHA to a selected patient. | 09-23-2010 |
| 20100247632 | STABILIZED SOLUBILITY-ENHANCED FORMULATIONS FOR ORAL DELIVERY - Methods and compositions are described whereby poorly water-soluble beneficial agents such as vitamins and co-factors are formulated into self-emulsifying formulas (SEF) and optionally sorbing the SEF into pores of porous solid particulates, or preparing supersaturated solutions (SSS) and sorbing the SSS into pores of porous solid particulates. These formulations are useful as dosage forms with oral availability. | 09-30-2010 |
| 20100247633 | Polypeptide Films and Methods - Disclosed herein are polypeptide multilayer films comprising a hybrid polypeptide comprising a first polypeptide segment and a second segment, the two segments being covalently joined by one or more non-peptidic linkages. The first segment comprises a polypeptide having a magnitude of net charge per residue of greater than or equal to 0.4, and a length of greater than or equal to about 12 amino acid residues. The second segment comprises a polypeptide or another polyelectrolyte. | 09-30-2010 |
| 20100247634 | Compositions and Methods for Inhibiting Gastric Acid Secretion - The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal. | 09-30-2010 |
| 20100255082 | Functionally Coated Breakable Tablets - Tablet and capsule formulations with a similar in vitro drug release profile for whole tablet and when broken and/or a bioequivalent drug release profile when taken whole or when broken are provided. In addition, coated splittable tablets are provided. Methods for production of these formulations and tablets and their administration are also provided. | 10-07-2010 |
| 20100260833 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 10-14-2010 |
| 20100266681 | FATTY ACID ALCOHOLS - The present invention relates to a lipid composition comprising at least omega-3 polyunsaturated alcohols, or pro-drugs thereof, which omega-3 polyunsaturated alcohols, or pro-drugs thereof, comprising at least (all-Z)-5,8,11,14,17-eicosapentaen-1-ol, or pro-drug thereof, and (all-Z)-4,7,10,13,16,19-docosahexaen-1-ol, or pro-drug thereof, and their use as a pharmaceutical, in particular for the treatment of elevated triglyceride levels. The invention also relates to methods for the preparation of these pro-drugs from marine oils. | 10-21-2010 |
| 20100266682 | POLYETHYLENE GLYCOL-COATED SODIUM CARBONATE AS A PHARMACEUTICAL EXCIPIENT AND COMPOSITIONS PRODUCED FROM THE SAME - Non-effervescent pharmaceutical compositions having at least one particle of carbonate coated by a layer of polyethylene glycol that substantially covers the at least one carbonate particle are described. Compositions are also described where the compositions include a weakly basic therapeutic agent, a first pH-modifying agent having at least one particle of carbonate coated by a layer of polyethylene glycol, and a second pH-modifying agent. The weakly basic therapeutic agent could be, but is not limited to, zolpidem or scopolamine. Compositions including zolpidem and scopolamine are used to treat insomnia and depression, respectively. | 10-21-2010 |
| 20100272791 | COMPOSITION HAVING EFFECT ON TREATMENT AND PREVENTION OF DRY EYE SYNDROME - Provided is a composition comprising, as an active ingredient, at least one material selected from the group consisting of uridine and derivatives thereof which promote synthesis of hyaluronic acid in animal and human cell and body, and a pharmaceutical preparation containing the same. The composition and pharmaceutical preparation of the present invention is effective in the treatment and prevention of dry eye syndrome. | 10-28-2010 |
| 20100285114 | PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN - The invention relates to pharmaceutical compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools as compared to Art 50®. The invention also relates to the methods for preparing such compositions. | 11-11-2010 |
| 20100291197 | HOT MELT-FILLED SOFT CAPSULES - The present invention relates to a soft capsule, comprising a capsule case and a filling material with at least one pharmacologically or physiologically active substance, characterized in that the capsule case is made by melt extrusion of thermoplastically processable polymer material, and the filling material is solid at under 10° C. and has a dripping point of higher than 55° C. | 11-18-2010 |
| 20100291198 | COMPOSITIONS OF PHYTOSTEROLS WITH ENHANCED BIOAVAILABILITY - A method for preparing porous microparticles containing phytosterol, by preparing a homogeneous melt of phytosterol and a partially water soluble component, cooling the melt to obtain an amorphous solid material, processing the material into a fine powder, and bringing the powder into contact with an aqueous phase under stirring conditions. A composition suitable for preparing a porous microparticle containing phytosterol. A porous microparticle containing phytosterol. A pharmaceutical or food product useful for lowering the cholesterol level in blood. | 11-18-2010 |
| 20100303900 | PREPARATION OF INJECTABLE SUSPENSIONS HAVING IMPROVED INJECTABILITY - Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability. | 12-02-2010 |
| 20100310647 | Enzymatic Synthesis of Polymers - The invention relates to new methods of enzymatic synthesis of polymers such as polyorganosilicones and polyesters, and new polymers made by these methods. | 12-09-2010 |
| 20100310648 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR - The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders. | 12-09-2010 |
| 20100310649 | SOLID LIPID MICROCAPSULES CONTAINING GROWTH HORMONE INNER CORE MICROPARTICLES - The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter. | 12-09-2010 |
| 20100330167 | Nanoparticles for protein drug delivery - The invention discloses the nanoparticles composed of chitosan, poly-γ-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery. | 12-30-2010 |
| 20100330168 | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF - Novel pharmaceutical compositions contain micronized progesterone and at least one oleic safflower oil referred to as safflower oil type II, and medicines comprising said compositions are useful in treating progesterone insufficiency in women. | 12-30-2010 |
| 20110002984 | FORMULATIONS COMPRISING EXINE SHELLS - A formulation containing an active substance encapsulated within an exine shell of a naturally occurring spore, together with a protective additive which is also encapsulated within the exine shell. | 01-06-2011 |
| 20110014278 | Compositions Comprising Dehydrated Micro-Organisms, Method for Preparing Same, and Uses Thereof - The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 μm. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products. | 01-20-2011 |
| 20110014279 | BIOACTIVE COMPLEX COMPOSITIONS AND METHODS OF USE THEREOF - A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, Omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides. The composition may optionally be further utilized for the prevention of hypercholesterolemia, bone (and teeth) mineral loss, treatment of mental health diseases, heart health, additional nutritional supplementation, and treatment of additional medical conditions. | 01-20-2011 |
| 20110027352 | COMPOUNDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN - The present invention relates to the use of a beta-adrenergic receptor agonist as active ingredient for the production of a medicament for use in the treatment of neuropathic pain, in particular neuropathic allodynia, in particular chronic neuropathic allodynia, and more generally for the production of medicaments for relieving pain. The principal field of application of the present invention is the biomedical field, and more specifically the therapeutics field. The present invention aims in particular to provide a medicament which can be used as a substitute for the antidepressants currently used to treat pain. It finds a use in the human and veterinary clinical field. | 02-03-2011 |
| 20110027353 | Therapeutic Delivery System - Therapeutic delivery systems are provided which, in a first embodiment, contain a plurality of multiphase capsules in which first and second therapeutic agents are contained in separate phases within said multiphase capsules, and are disposed to deliver said first and therapeutic agents by at least two different delivery mechanisms. | 02-03-2011 |
| 20110027354 | ANTI-PARKINSONIAN COMPOUNDS - The present application describes a composition comprising a neuroprotective effective amount of N-methyl-N-propynyl-2-phenylethylamine (MPPE). | 02-03-2011 |
| 20110027355 | HIGH-FLUIDITY AND NON-CAKING PULVERULENT CRYSTALLINE MALTITOL COMPOSITION - A pulverulent crystalline maltitol composition, is characterized in that it has a laser volume mean diameter between 10 and 150 μm; in that it has a maltitol content between 80 and 99.9% by weight; in that at least 50% by weight of its particles flow through a sieve having a cut-off threshold of 2000 μm according to a test A1; in that at least 35% by weight of its particles flow through a sieve having a cut-off threshold of 2000 μm according to a test A2; and in that it includes from 0.1 to 20% by weight of at least one water-insoluble anti-caking agent, the anti-caking agent having a hygroscopicity, determined according to the test B, between 2.5 and 25%. This composition is not subject to caking, and finds applications in the food and pharmaceutical fields. | 02-03-2011 |
| 20110033526 | PHARMACEUTICAL COMPOSITION OF ANTIBIOTICS AND PREBIOTICS FOR PREVENTING AND TREATING DYSBIOSIS DURING ANTIBACTERIAL THERAPY - The invention relates to medicine and pharmacology, in particular to pharmaceutical compositions containing the following antimicrobial preparations: antibiotics and sulphanylamides combined with prebiotic in the form of a lactulose. The composition is used for preventing enteral dysbiosis arising during antibiotic therapy using the wide range of preparations. The inventive pharmaceutical composition contains antibiotic or a sulphanylamide preparation and lactulose, wherein the antibiotic particle size ranges from 20 to 160 mkm, the sulphanylamide preparation particle size ranges from 40 to 150 mkm and the lactulose has a particle size equal to or less than 0.3 mm and the purity of at least 97%, with the ratio of the antibiotic and lactulose ranging from 1:0.1 to 1:100, and the ratio of the sulphanylamide preparation and lactulose of 1:12, said composition being internally administered. The inventive preparations contribute to the preservation of antibiotic-damaged intestinal flora by producing selective prebiotic action on the growth of dominant types of microflora of the large intestine, such as lactobacilli and bifidobacteria. | 02-10-2011 |
| 20110033527 | Opthalmic compositions of cyclosporin - Lipid-polymer compounds are used to solubilize cyclosporin. Diacylglycerol-polyethyleneglycols (DAG-PEGs) are especially useful in this regard. A preferred embodiment of the invention is an aqueous solution of cyclosporin suitable for opthalmic use. | 02-10-2011 |
| 20110038927 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS - A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. | 02-17-2011 |
| 20110045062 | FORMULATION - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 02-24-2011 |
| 20110052679 | SOLID NAPROXEN CONCENTRATES AND RELATED DOSAGE FORMS - The invention provides a composition consisting essentially of a solid naproxen concentrate, wherein the solid naproxen concentrate comprises (a) a solid naproxen free acid and (b) a solid naproxen alkali salt, and wherein at least 90% of the weight of the solid naproxen concentrate is naproxen free acid and naproxen alkali salt, as well methods of producing such a solid naproxen concentrate. | 03-03-2011 |
| 20110052680 | ENCAPSULATION OF OXIDATIVELY UNSTABLE COMPOUNDS - An encapsulated material containing an oxidation-sensitive core is covered by at least a dried phospholipid layer, and contains at least one phytosterol in the core, the phospholipid layer or in a further layer or layers. By using microencapsulation, oxidatively unstable materials may be provided with a synthetic protective barrier and rendered less susceptible to oxidative degradation. | 03-03-2011 |
| 20110052681 | Pharmaceutical compositions of entacapone co-micronized with sugar alcohols - The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions. | 03-03-2011 |
| 20110059164 | ENCAPSULATION OF OXIDATIVELY UNSTABLE COMPOUNDS - An encapsulated material containing an oxidation-sensitive core is covered by at least a dried synthetic organelle layer and optional additional ingredients in the organelle layer or additional layers. By using microencapsulation to mimic or otherwise adapt the storage concepts used by seeds to protect triacylglycerol cores, oxidatively unstable materials may be provided with a synthetic, seed-like oxygen-resistant protective barrier and rendered less susceptible to oxidative degradation. | 03-10-2011 |
| 20110059165 | SEAMLESS ALGINATE CAPSULES - The present invention is directed to a dried seamless capsule comprising an alginate shell membrane encapsulating fill material, wherein: (i) said alginate shell membrane comprises a polyvalent metal ion alginate having: (a) an average M content of from 50%-62% by weight based on the weight of the M and G content, and (b) a viscosity of 35 to 80 cps when measured as a monovalent metal ion alginate in a 3.5% water solution at 20° C. using a Brookfield LV viscometer at 60 rpm and spindle # | 03-10-2011 |
| 20110064797 | CAPSULE OF THERMOGENIC CELLS FOR TREATING A METABOLIC DISEASE - Described herein are methods and devices for treating a metabolic disease that involve implanting a micro-device into a tissue of a subject having a metabolic disease. The micro-device includes a plurality of thermogenic cells encapsulated in a biocompatible capsule. The capsule includes a core to accommodate the plurality of thermogenic cells and a porous immunoprotective membrane that allows for metabolic interaction between the plurality of thermogenic cells and the tissue. | 03-17-2011 |
| 20110064798 | SUSPENSION CONTAINING HYDRONIUM STABILIZED COLLOIDAL SILICIC ACID NANOPARTICLES, FORMULATION OBTAINED FROM THE SAID DILUTESUSPENSION, POWDER OBTAINED FROM THE SAID DE-HYDRATED SUSPENSION, COMPOSITIONS OBTAINED FROM THE SAID POWDER, PREPARATION AND USE - The present invention relates to hydronium stabilized silicic acid nanoparticles, to the formulation obtained from the said diluted suspension, to the powder obtained from the said dehydrated suspension and to the preparation or dosage form obtained from the said suspension, formulation or powder, to their preparation and their use in all kinds of applications in the domains of food, medicine, pharmaceutics, cosmetics. The present invention provides a stable suspension of colloidal silicic acid nanoparticles having a pH lower than 0.9, a molar silicon concentration between 0.035 and 0.65, a free water concentration of at least 30% (w/v) and a ratio between hydronium ion and Si molar concentrations higher than 2 and preferably inferior to 4. The present invention further provides a method for preparing a stable suspension of colloidal silicic acid nanoparticles, which comprises the steps of providing an aqueous inorganic or organic silicon solution and quick mixing said aqueous inorganic or organic silicon solution with water containing a strong acidic compound at a temperature inferior at 30° C., preferably comprised between 1 and 25° C., to form a suspension of colloidal silicic acid nanoparticles having a pH lower than 0.9, stabilized by hydronium ions, the ratio between hydronium ions and Si molar concentrations being higher than 2 and preferably inferior to 4, for a molar silicon concentration between 0.035 and 0.65 and a free water concentration of at least 30% (w/v). | 03-17-2011 |
| 20110081410 | THERAPEUTIC AGENT FOR LOCAL INFLAMMATION - The agents of the present invention comprise, as a main ingredient, a polyvalent metal inorganic-salt nanocapsule which encapsulates a retinoid such as retinoic acid. The agents could penetrate into a joint when applied to the skin and induce hyaluronic acid production in a synovial membrane or chondrocyte. Moreover, application of the nanocapsule of the present invention to the skin for a certain period of time lowered the values of inflammatory cytokines and MMPs in the blood. | 04-07-2011 |
| 20110081411 | Orally Administered Corticosteroid Compositions - The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention. | 04-07-2011 |
| 20110081412 | ORALLY DISINTEGRABLE TABLETS - An orally disintegrable tablet, of the present invention, which comprises (i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration. | 04-07-2011 |
| 20110086092 | PHARMACUETICAL TABLETS CONTAINING A PLURALITY OF ACTIVE INGREDIENTS - Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry-over and intermixing are minimized in the manufacture process. | 04-14-2011 |
| 20110086093 | METHOD FOR INCREASING LACTOSE TOLERANCE IN MAMMALS EXHIBITING LACTOSE INTOLERANCE - The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely, | 04-14-2011 |
| 20110091533 | Amphiphilic polymer capsules and related methods of interfacial assembly - Polymer capsules from amphiphilic graft copolymers comprising reactive, hydrophobic polyolefin backbones, and hydrophilic poly(ethylene glycol) (PEG) grafts are produced by self-assembly of the polymers at the oil-water interface, and crosslinking the assembly with bis-cyclooctene PEG derivatives in conjunction with ring-open metathesis polymerization catalysts. The use of the graft copolymer architecture in capsule synthesis provides significant opportunities to tune both the surface properties, in terms of recognition, and the membrane properties, in terms of mechanical strength, encapsulation, and release. | 04-21-2011 |
| 20110091534 | COMPOSITIONS COMPRISING POLYMERIC MICELLES FOR DRUG DELIVERY - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. | 04-21-2011 |
| 20110091535 | SOLID PHARMACEUTICAL FORMULATION - The present invention relates to a sustained-release solid pharmaceutical formulation comprising (a) an active medical ingredient, (b) a pre-gelatinized starch in an amount of 10 to 90% by weight based on the whole weight of the formulation and (c) one or more kinds of enteric ingredients. | 04-21-2011 |
| 20110091536 | COMPOSITIONS COMPRISING EUPHORBIA PROSTRATA AND PROCESS OF PREPARATION THEREOF - Oral pharmaceutical compositions comprising dry extract of | 04-21-2011 |
| 20110097394 | TYPE A GELATIN CAPSULE CONTAINING PUFA IN FREE ACID FORM - A pharmaceutical formulation comprising at least one omega-3 polyunsaturated fatty acid in free acid form or a pharmacologically acceptable derivative thereof is contained in a soft gelatin capsule characterised in that the capsule comprises gelatin extracted by an extraction process comprising acid pre-treatment of a collagen source. One advantage of the present invention over a soft gelatin capsule containing the same formulation but comprising gelatin extracted by an extraction process comprising alkali pre-treatment of the collagen source is that the present invention does not harden significantly over time and thus has a longer shelf life. | 04-28-2011 |
| 20110097395 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use - The present invention is directed to oral pharmaceutical compositions of buprenorphine and it pharmaceutically acceptable salts and the use thereof. | 04-28-2011 |
| 20110104264 | Gastric acid secretion inhibiting composition - A method for the treatment of at least one symptom of gastro-esophageal reflux disease (GERD) in a human suffering from GERD administers an oral pharmaceutical dosage form into a gastro-intestinal tract of a human suffering from GERD. The oral pharmaceutical dosage form contains an acid susceptible proton pump inhibitor or salt thereof (PPI), an H2 receptor antagonist or salt thereof (H2RA), a pharmaceutically acceptable carrier, and optionally an antacid agent and/or alginate. The PPI is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, leminoprazole, their pharmaceutically acceptable salts, enantiomers and salts of enantiomers and is in a form that protects the PPI from degradation in a stomach. The H2RA is selected from cimetidine, ranitidine, nizatidine and famotidine, their pharmaceutically acceptable salts, isomers and salts of isomers. The PPI is administered in combination with the H2RA for passage into a small | 05-05-2011 |
| 20110104265 | COMPOSITIONS AND METHODS OF TARGETED NANOFORMULATIONS IN THE MANAGEMENT OF OSTEOPOROSIS - A composition and method for treating a bone condition of an animal. The compostion includes nanoparticles; a targeted moiety covalently bonded to an outer surface of each nanoparticle; and osteoblast stimulating molecules encapsulated within each nanoparticle. The method for treating a bone condition includes introducing the composition into the animal. | 05-05-2011 |
| 20110104266 | MULTIMICROPARTICULATE PHARMACEUTICAL FORMS FOR ORAL ADMINISTRATION - The object of the present invention is to minimize the risks of dose dumping associated with the concomitant consumption of alcohol and certain modified-release pharmaceutical or dietetic forms. | 05-05-2011 |
| 20110123604 | ABSORBENT POLYMERIC COMPOSITIONS WITH VARYING COUNTERION CONTENT AND THEIR METHODS OF PREPARATION AND USE - Cross-linked polyelectrolyte polymers with bound counterions that absorb about 20-fold or more of their mass in saline such as physiological saline a with the proviso that sodium does not exceed 60% of total bound counterions when hydrogen is the sole other counterion, are disclosed. Methods of preparing the disclosed polymers and for treating subjects such as patients in need of fluid removal and/or modulation of ions (e.g., sodium and/or potassium) are provided. | 05-26-2011 |
| 20110123605 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 05-26-2011 |
| 20110129528 | SUSTAINED-RELEASE CHITOSAN CAPSULES COMPRISING CHITOSAN AND PHYTIC ACID - The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material. Further, since the capsule of the present invention has a pH-dependent sustained-release mechanism which can minimize the release of a soluble active ingredient in the stomach and gradually release in the intestine, it is possible to regulate sustained-release of a soluble active ingredient. | 06-02-2011 |
| 20110135718 | VIRAL PARTICLE-LIKE STRUCTURE IN PHYSIOLOGICAL CONDITIONS, AND METHOD OF FORMING IT - There is provided a novel method of forming uniform viral particles under physiological conditions. The method of forming uniform-sized viral particle aggregates composed of viral protein is characterized by incubating a viral protein such as SV40 virus VP1 at pH 5.0 to 7.0, room temperature, in the presence of 130 mM to 170 mM sodium chloride and 1.5 mM to 2.5 mM divalent cation, and in the presence of a particle formation acceleration factor such as SV40 VP2. For encapsulation of a substance to be encapsulated in the viral particles, the substance to be encapsulated is included during the incubation. | 06-09-2011 |
| 20110135719 | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion. | 06-09-2011 |
| 20110135720 | Polymer coatings containing phytochemical agents and methods for making and using same - This invention relates to compositions comprising a polymer base incorporating antifouling compositions suitable for use in aquaculture, marine and architectural systems as paints, structures or coatings. In particular, the present invention relates to a polymer based coating incorporating a biocidal antifouling composition suitable for use with aquaculture equipment. The present invention provides polyethylene compositions and latex compounds which may comprise at least one environmentally benign phytochemicals suitable for use in preventing the colonization of a treated surface by a variety of biological species. The compositions of the invention may further comprise control release agents such as, for example, micro-encapsulation of the phytochemicals to maintain sustained and prolonged release of the biocidal agents at the treated surface. | 06-09-2011 |
| 20110142924 | Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein - A bioengineering, in particular to develop novel probiotic preparations based on | 06-16-2011 |
| 20110142925 | Film Coating For Tablets And Caplets - The present invention relates to novel coating compositions for application to solid dosage forms such as tablets or caplets, solid dosage forms coated with the composition, and methods of preparing said coating compositions. | 06-16-2011 |
| 20110150985 | METHODS FOR PREPARING PHARMACEUTICALS BY EMULSION AGGREGATION PROCESSES - A method for making a pharmaceutical by emulsion aggregation, the method including emulsifying a first pharmaceutical agent and a biodegradable resin to form a primary emulsion of pre-aggregated particles in a slurry; aggregating the pre-aggregated particles to form aggregated pharmaceutical particles in the slurry; and isolating the pharmaceutical particles. The method may be used to make time-released, multi-formulation, and inhalable pharmaceuticals. | 06-23-2011 |
| 20110150986 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHO OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo. | 06-23-2011 |
| 20110150987 | MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE - The present invention relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm. | 06-23-2011 |
| 20110150988 | DIETARY SUPPLEMENT COMPOSITION FOR BLOOD LIPID HEALTH - A human or animal dietary supplement composition comprising one or more long chain (C24-C36) primary alcohols (policosanols) dispersed in food-grade oils or fats where the policosanol particle size is substantially less than ten (10) microns. The composition (Nanocosanol™) is effective and convenient for supporting blood lipid health. | 06-23-2011 |
| 20110159082 | PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHOD FOR THE PREPARATION THEREOF - The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent. | 06-30-2011 |
| 20110165233 | STABILITY ADDITIVES FOR DRY DHA DOSAGE FORMS - The use of additives to stabilize DHA when compressed into tablets, or filled as a powder into capsules, for oral administration. | 07-07-2011 |
| 20110171293 | HARD CAPSULE COMPOSITION AND METHOD OF USE - A method for making clear hard vegetarian gelatin free two piece capsules by creating the first phase of the biphasic system using seaweed extract, gellan gum, metallic element, maltol extract, seaweed extract and water. A filler is created for the first phase of the biphasic network by blending water, galactomannan extract, and cellulose. The filler is then mixed into the system forming a biphasic system, a first pin is then dripped into the blend and then a second pin is then dripped into the blend. Blowing hot air on the dipped pins, which then blows away water on the outer surface of the dipped pins to bond and lock moisture to the cellulose. A large diameter capsule piece is removed from the first pin and a small diameter capsule piece is removed from the second pin, wherein each capsule piece has an outer surface which is mechanically and dimensionally stable. | 07-14-2011 |
| 20110171294 | Enzyme composition and application thereof in the treatment of pancreatic insufficiency - The present invention relates to a composition of at least one protease and a mode of application for treating patients suffering from pancreatic enzyme insufficiency, pancreatitis or cystic fibrosis. The composition of enzymes comprises at least one protease which has a pH optimum below 5.0 and wherein said protease is further active in the presence of pepsin. In a preferred embodiment, said protease is of microbial origin. | 07-14-2011 |
| 20110177161 | PHARMACEUTICAL COMPOSITIONS OF [5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN - There is provided a powder composition for use in a pharmaceutical product, the composition including a) 5(S)-(2′-hydroxyethoxy)-20(S)-CPT; at least one cyclodextrin; wherein 5(S)-(2′-hydroxyethoxy)-20(S)-CPT includes less than 5% of 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. Preferably, in the powder composition, 5(S)-(2′-hydroxyethoxy)-20(S)-CPT is substantially free from said 5(R)-(2′-hydroxyethoxy)-20(S)-CPT. | 07-21-2011 |
| 20110177162 | DEGRADABLE MICROCAPSULES - The invention relates to microcapsules consisting of a polymer degradable by a polypeptide comprising a drug or other compound of interest and a genetically engineered cell expressing said polypeptide in response to a triggering compound, and to methods of directed release of the compound of interest. The preferred polymer is optionally modified cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. The expression system for cellulase is, for example, based on TET and doxycycline, or E.REX and erythromycin. In another example, expression of cellulase is triggered by luteinizing hormone, which can be used for artificial insemination with microcapsules carrying sperm. | 07-21-2011 |
| 20110177163 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS A - The present application provides compositions and methods useful for treating hepatitis A. In particular, while hepatitis A vaccines are currently limited to parenteral administration routes (i.e., intramuscular injection), we have identified compositions that induce a protective response when administered orally. | 07-21-2011 |
| 20110182983 | HUMAN IMMORTALISED NEURAL PRECURSOR CELL LINE - The present invention relates to an immortalised human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalised using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours. | 07-28-2011 |
| 20110182984 | High Content Sodium Ibuprofen Granules, Their Preparation And Their Use In Preparing Non-Effervescent Solid Dosage Forms - Granules of racemic sodium ibuprofen dihydrate formed from components specified herein have very desirable properties and can be effectively used in conventional rotary press tableting equipment without operational difficulties often encountered in actual practice. Their preparation by a wet granulation process, the wet granule compositions, formulations adapted for preparation of solid dosage forms utilizing a rotary press, solid dosage forms, and methods of preparing solid dosage forms in a rotary press are also described. | 07-28-2011 |
| 20110189269 | Extended release composition containing tramadol - The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts. | 08-04-2011 |
| 20110189270 | Differential Loading Of Drug-Eluting Medical Devices - A medical device includes a substrate having at least one surface. The surface has a central portion and a peripheral portion. At least one bioactive agent is disposed over at least a portion of the surface. The medical device having a concentration gradient of the at least one bioactive between the central and peripheral portions. | 08-04-2011 |
| 20110189271 | PHARMACEUTICAL FORMULATIONS OF ACID-LABILE DRUGS - Pharmaceutical formulations comprising inert cores that are coated with a layer comprising an amorphous dexlansoprazole sodium salt formed in-situ, further sequentially coated with an intermediate layer and an enteric coating layer. Coated cores may be further formulated to produce tablets or capsules. | 08-04-2011 |
| 20110189272 | PHARMACEUTICAL PREPARATION CONTAINING GABAPENTIN - A method for preparing a gabapentin granulate comprising melt granulating gabapentin with polyethylene glycol having a melting point comprised between 50 and 80° C. | 08-04-2011 |
| 20110195115 | HYDROPHILIC AMINO ACID-CONTAINING PREPARATION HAVING IMPROVED TASTE - The present invention provides a hydrophilic amino acid-containing preparation wherein the taste of the hydrophilic amino acid is improved without damaging the appearance, flavor, storage stability and so on. It is further intended to provide a hydrophilic amino acid-containing preparation in which quick release of the hydrophilic amino acid from the preparation is assured, if necessary. It is furthermore intended to provide a hydrophilic amino acid-containing preparation where a solid agent containing a hydrophilic amino acid is coated with a coating agent comprising a flavoring agent and a water-soluble high molecular material. | 08-11-2011 |
| 20110195116 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM - This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed. | 08-11-2011 |
| 20110200668 | PHARMACEUTICAL COMPOSITION FOR PREVENTING DYSBIOSIS ASSOCIATED WITH ENTERAL ADMINISTRATION OF ANTIBIOTICS - In the first variant, the pharmaceutical composition comprises antibiotic and prebiotic in the form of oligosaccharide of a group comprising fructooligosaccharides, galactooligosaccharides, maltooligosaccharides and isomaltooligosaccharides the polymerisation degree of which ranges from 2 to 10, the particle size is equal to less than 0.3 mm and the purity is of at least 95%, wherein the antibiotic particle size ranges from 20 to 200 mkm and the antibiotic and oligosaccharide are contained with a mass ratio ranging from 1:1 to 1:100 respectively. In the second variant, the pharmaceutical composition comprises antibiotic which is in the form of a powder with the particle size ranging from 20 t0 200 mkm and is selected form a group consisting of beta-lactams, including the combination thereof with bacterial betalactamase inhibitors, azalides, fluoroquinalones, amphenicols, glycopeptides, ansamycins, nitrofurans, phosphonic acid derivatives, cycloserine and trimetoprim. The prebiotic is in the form of a powder oligosaccharide, the polymerisation degree of which ranges from 2 to 10, the particle size is equal to less than 0.3 mm and the purity is of at least 95%, wherein the antibiotic and oligosaccharide are contained with a mass ratio ranging from 1:1 to 1:100 respectively. The above-mentioned compositions are used for preventing intestinal dysbiosis during antibiotic therapy and are perorally administered. The inventive composition produces a stimulating effect on intestinal lactobacilli and bifidobacteria simultaneously inhibiting the growth and proliferation of extraneous or pathogenic microflora. | 08-18-2011 |
| 20110212169 | METHOD FOR PRODUCING POWDER CONTAINING NANOPARTICULATED SPARINGLY SOLUBLE DRUG, POWDER PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME (As Amended) - Disclosed are a method for preparing a powder containing a nanoparticulated sparingly soluble drug, a powder prepared thereby, and a pharmaceutical composition containing the same. The disclosed method includes: providing a uniformly dispersed solution of a sparingly soluble drug which is formed into nanoparticles in the presence of a surface stabilizer; mixing the uniformly dispersed solution with a water-soluble dispersant solution; and drying the mixed solution to obtain the powder. | 09-01-2011 |
| 20110217368 | BACTERIAL COMPOSITIONS FOR PROPHYLAXIS AND TREATMENT OF DEGENERATIVE DISEASE - The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 μmol glycodeoxycholic acid (GDCA)/gram/hour and >2 μmol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 μmol GDCA/g/hr and >7 μmol TDCA/g/hr when measured over 30 minutes. | 09-08-2011 |
| 20110223242 | NANOPARTICLES CONTAINING A PEPTIDE, VECTORS CONTAINING SAID NANOPARTICLES, AND PHARMACEUTICAL USES OF SAID NANOPARTICLES AND VECTORS - The invention relates to nanoparticles comprising a matrix containing at least one polysaccharide as well as the peptide P140 having the sequence SEQ ID NO: 1 or an analog thereof, said polysaccharide preferably being a polysaccharide bearing one or more negatively-charged functional groups. The invention also relates to a carrier for oral administration that comprises a carrier including at least one nanoparticle as defined above and either containing or not containing a dispersant. | 09-15-2011 |
| 20110223243 | ARTIFICIAL OXYGEN CARRIERS AND USE THEREOF - The invention relates to dispersions of artificial oxygen carriers, wherein the dispersions contain capsules with reversible oxygen storage capacity, the capsules comprising an oxygen-permeable capsule material, that contains and/or encloses fluorinated, particularly perfluorinated hydrocarbons, preferably perfluorocarbons. The dispersions are particularly suitable as a blood substitute, preferably for the purpose of transfusion, e.g. in states of blood loss of the human or animal body, in particular following surgical interventions, accidents, injuries etc, or for the prophylactic treatment and/or treatment by therapy of ischaemic states or states following a reperfusion. | 09-15-2011 |
| 20110236472 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF A WATER SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICALLY ACTIVE SUBSTANCE - A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises amorphous particles of <100 nm of a poorly water soluble complex of the API with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, which particles are entrapped in nanoparticles formed a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, the w/w-ratio of Na-salt of N-alltrans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester to the complex is about 0.5:1 to about 20:1. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer. | 09-29-2011 |
| 20110236473 | STABLE ALISKIREN FORMULATIONS - An oral pharmaceutical formulation, made up of croscarmellose sodium and internal granules including a pharmaceutically acceptable salt or polymorph of aliskiren and stearic acid. | 09-29-2011 |
| 20110244031 | POROUS TABLETS AS CARRIERS FOR LIQUID FORMULATIONS - A tablet composition, which in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable oily substance, may be produced in large-scale batches and stored until use; and tablets loaded with a pharmaceutically acceptable oily substance as well as a method for the preparation thereof. The tablet composition comprises a release enhancing agent and provides high and/or consistent release of the pharmaceutically acceptable oily substance, in particular release of a pharmaceutically acceptable, but substantially water-insoluble, oily substance. | 10-06-2011 |
| 20110244032 | DISPERSIBLE PHOSPHOLIPID STABILIZED MICROPARTICLES - Rapidly dispersing solid dry therapeutic dosage form comprised of a water insoluble compound existing as a nanometer or micrometer particulate solid which is surface stabilized by the presence of at least one phospholipid, the particulate solid being dispersed throughout a bulking matrix. When the dosage form is introduced into an aqueous environment the bulking matrix is substantially completely dissolves within less than 2 minutes thereby releasing the water insoluble particulate solid in an unaggregated and/or unagglomerated state. The matrix is composed of a water insoluble substance or therapeutically useful water insoluble or poorly water soluble compound, a phospholipid and optionally also at least one non-ionic, anionic, cationic, or amphipathic surfactant, together with a matrix or bulking agent and if needed a release agent. The volume weighted mean particle size of the water insoluble particle is 5 micrometers or less. | 10-06-2011 |
| 20110244033 | TAMSULOSIN PELLETS FOR FIXED DOSE COMBINATION - The invention relates to a population of tamsulosin-comprising pellets for oral administration of a combination dosage form containing physically separated a tamsulosin dose in the form of the population of the tamsulosin comprising pellets and at least one other dose of a pharmaceutically active substance, said pellets comprising tamsulosin hydrochloride uniformly dispersed in a carrier matrix, wherein (i) said pellets in the population have a size of less than about 1.4 mm and, advantageously, at least 90% of the pellets have a size of larger than 0.30 mm; and (ii) an average content of tamsulosin hydrochloride in the population of pellets is between about 0.15-3.00 weight percent, calculated on a dry pellet basis, to a process of making such population of pellets, and to their use. | 10-06-2011 |
| 20110256216 | Probiotic Confection and Lipid Compositions - The present application relates to probiotic confection-based compositions comprising lactic acid-producing bacteria and oil-based compositions comprising the same. | 10-20-2011 |
| 20110262531 | NANOPARTICULATE SYSTEM, PROCESS FOR THE PREPARATION OF THE SAME, USE OF THE SAME, PHOTOPROTECTIVE COMPOSITION, PROCESS FOR THE PREPARATION OF THE SAME, METHOD OF PREVENTION OF DISEASES OF THE SKIN - The present invention describes cosmetic nanotechnology, comprising polymeric nanoparticles containing oil and UV filter, photoprotective compositions comprising polymeric nanoparticles described herein, methods of prevention of diseases of the skin, and processes for the preparation of the polymeric nanoparticles described herein. | 10-27-2011 |
| 20110287091 | CHRONOTHERAPEUTIC PHARMACEUTICAL COMPOSITION - The present invention relates to chronotherapeutic pharmaceutical compositions and a method of preparing the same. The composition comprises of at least one active ingredient, a pH independent agent and a hydrophilic agent. The active ingredient in the composition is coated with the pH independent agent. The composition provides a dual controlled release system, which aids in an initial lag time of 4-6 hours and controlled release of the active ingredient up to 24 hours. | 11-24-2011 |
| 20110293710 | Immunomodulatory properties of lactobacillus strains - A specific method is provided of improving immunomodulatory properties of | 12-01-2011 |
| 20110293711 | Utilization of Dialkylfumarates - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | 12-01-2011 |
| 20110293712 | COAXIALLY ENCAPSULATED CELL SUSPENSIONS AND MICROTISSUES - The present invention provides for the coaxial encapsulation of a plurality of cells in a single elongated compartment. By this encapsulation, the cells are protected by at least one layer of separation material and kept in close contact, which leads to a better vitality of the encapsulated cells and consequently results in higher chances to form microtissue. Methods and devices for the production of such encapsulated cell compartments are disclosed as well as medical uses of such compartments in cell, tissue therapy and tissue engineering. | 12-01-2011 |
| 20110293713 | PHARMACEUTICAL FORMULATIONS COMPRISING NSAID AND PROTON PUMP INHIBITOR DRUGS - Aspects of the present application relate to pharmaceutical formulations comprising a nonsteroidal anti-inflammatory drug, together with a proton pump inhibitor drug, to reduce the incidence of gastrointestinal complications associated with chronic therapy with a nonsteroidal anti-inflammatory drug. Specific aspects of the application relate to fixed dose combinations comprising aspirin, or a derivative thereof, and omeprazole or esomeprazole, or pharmaceutically acceptable salts, solvates, or hydrates thereof. | 12-01-2011 |
| 20110300207 | METHOD OF TREATING POST-SURGICAL ACUTE PAIN - A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients. | 12-08-2011 |
| 20110300208 | SEGMENTED PHARMACEUTICAL DOSAGE FORMS - A pharmaceutical tablet adapted for accurate division of a dose of a drug into two or more smaller doses, which tablet has two or more segments. | 12-08-2011 |
| 20110305753 | Treatment of celiac disease with IgA - A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral adminstration to the subject suffering from food allergy or food intolerance an IgA or an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgA and IgM are effective when administered orally. | 12-15-2011 |
| 20110311617 | ORAL VACCINE - The present invention provides an oral vaccine against a bacterial infectious disease (e.g., typhoid fever, cholera, or dysentery). The oral vaccine of the present invention is a capsule formulation in which a transformed microorganism that expresses a flagellin antigen protein or that secretes a flagellin antigen protein out of the cell of the microorganism is encapsulated with an acid-resistant membrane. Examples of the microorganism include intestinal bacteria belonging to the genus | 12-22-2011 |
| 20110318410 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 12-29-2011 |
| 20120003303 | ORAL ENTERIC ANTIDEPRESSANT FORMULATION - Pharmaceutical presentations of phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are protected from binding to active ingredient in the stomach. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: (I) wherein n is 0, 1 or 2; R1 is a branched or straight chain C1-5 alkyl or C3-6 cycloalkyl optionally substituted with hydroxyl, or one or more halogens; and X | 01-05-2012 |
| 20120003304 | Solid Forms - The present invention is directed to a solid form comprising an active ingredient and croscarmellose, wherein: (i) the croscarmellose has a median particle size of ≧56 microns, (ii) the croscarmellose is present in an amount of ≧4% by weight based on the total weight of the solid form, and (iii) the solid form is a tablet, capsule, caplet, lozenge or granule. The present invention is also directed to a method of decreasing the disintegration time (for example, in water) of a solid form that comprises croscarmellose in an amount ≧4% by weight based on the total weight of the solid form. | 01-05-2012 |
| 20120009254 | Respiratory Syncytial Virus Antigenic Compositions and Methods - Multilayer films comprise polypeptide epitopes from RSV. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films include at least one designed peptide that includes one or more polypeptide epitopes from RSV. Specifically, the multilayer films include two polypeptide epitopes from RSV, such as an epitope that elicits a specific T-cell response such as a cytotoxic T-cell response, and an epitope that elicits a specific antibody response. | 01-12-2012 |
| 20120015027 | F, G, H, I and K Crystal Forms of Imatinib Mesylate - The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-( | 01-19-2012 |
| 20120021048 | Combination Dosage Compositions Comprising a Cholesterol-Lowering Agent, a Renin-Angiotensin System Inhibitor, an Antioxidant Agent and an Antiplatelet Agent for Treatment and Prevention of Cardiovascular Disease - The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an antioxidant compound for the treatment and/or prevention of cardiovascular disease. | 01-26-2012 |
| 20120021049 | Single Daily Dosage Form for Prevention and Treatment of Metabolic Syndrome - The present invention is in the fields of medicine, pharmaceuticals, nutraceuticals, endocrinology and cardiology. The invention provides compositions comprising a statin, an inhibitor of the angiotensin converting enzyme, an antiplatelet compound and an anti-hyperglycemic compound for use in the treatment and/or prevention of cardiometabolic risk factors of Metabolic Syndrome and treatment and/or prevention of Metabolic Syndrome. The present invention provides for the use of such compositions in the manufacture of products for treatment and/or prevention of Metabolic Syndrome. The biguanide metformin of the composition could be present in extended release form allowing its use together with the other drugs in a single dosage form at low dose. This combination of drugs in a single daily dosage greatly improves compliance and adherence to treatment which is a critical factor for treating patients with Metabolic Syndrome. | 01-26-2012 |
| 20120021050 | NANOPARTICLE FORMULATED GLYCOLIPID ANTIGENS FOR IMMUNOTHERAPY - A composition for stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells includes a glycolipid antigen and a nanoparticle conjugated with the glycolipid antigen. The glycolipid antigen and the nanoparticle are not antigenic in mouse and human being. The composition can further include covalent or non-covalent connection between the glycolipid antigen and the nanoparticle. The glycolipid antigen is alpha-galactosylceramide or an analog of that. The nanoparticle can be a polymer. A production method of the composition includes preparing a nanoparticle and a glycolipid antigen and loading the glycolipid antigen to the nanoparticle. The glycolipid antigen can be coated onto the surface of the nanoparticle or encapsulated within the nanoparticle. A method of stimulating NKT cells to produce anti-cancer and anti-viral cytokines without causing anergy of NKT cells is also provided. | 01-26-2012 |
| 20120027847 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY - The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide. | 02-02-2012 |
| 20120027848 | Enzyme Delivery Systems and Methods of Preparation and Use - This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders. | 02-02-2012 |
| 20120027849 | STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS - The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from β-adrenergic receptor blocking agent, ACE inhibitor and diuretic. The lipid lowering agent is selected from HMG Co-enzyme-A reductase inhibitor. The pharmaceutical composition made as per present invention a) overcomes any drug-drug interactions, b) exhibits pharmacokinetic and pharmacodynamic profile of individual therapeutic agent, c) has minimal side effects. The invention provides multi-component composition (MCC) to increase adherences to therapy. The MCC as per present invention provides compositions that maintain activity of all active ingredients without significant increase in adverse event profile. The present invention further relates to a method of preparing the said pharmaceutical composition. | 02-02-2012 |
| 20120027850 | Compositions and Methods for Treatment of Aortic Fibrosis - The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of aortic fibrosis and other associated conditions. | 02-02-2012 |
| 20120034297 | Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3- ,4,b]indol]-4-amine - A pharmaceutical dosage form for administration twice daily, once daily or less frequently, which contains 6′-fluoro-(N-methyl- or N,N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine or a physiologically acceptable salt thereof. | 02-09-2012 |
| 20120039996 | USES OF RED YEAST RICE IN TREATING DENGUE VIRUS INFECTION - This invention provides a method of using red yeast rice fermented product to treat a subject having a disease caused by dengue virus. In one embodiment, the red yeast rice is prepared with the yeast | 02-16-2012 |
| 20120039997 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 02-16-2012 |
| 20120045504 | ORAL DRUG DEVICES AND DRUG FORMULATIONS - Compositions containing a drug to be delivered and at least one chemical permeation enhancer (CPE), and methods of making and using these compositions are described herein. In a preferred embodiment, the compositions contain two or more CPEs which behave in synergy to increase the permeability of the epithelium, while providing an acceptably low level of cytotoxicity to the cells. The concentration of the one or more CPEs is selected to provide the greatest amount of overall potential (OP). Additionally, the CPEs are selected based on the treatment. CPEs that behave primarily by transcellular transport are preferred for delivering drugs into epithelial cells. CPEs that behave primarily by paracellular transport are preferred for delivering drugs through epithelial cells. Also provided herein are mucoadhesive oral dosage forms. In a preferred embodiment, the oral dosage form is a multi-compartmental device, containing (i) a supporting compartment, (ii) drug compartment and (iii) mucoadhesive compartment. | 02-23-2012 |
| 20120045505 | FIXED DOSE DRUG COMBINATION FORMULATIONS - Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets. | 02-23-2012 |
| 20120058179 | Apparatus and process for encapsulating microparticles with liquid in soft gel capsules - The invention provides an apparatus for producing soft gel capsules having encapsulated therein microparticles, nanoparticles and fluids, said apparatus comprising: (a) two spreader boxes; (b) two casting drums; (c) a pair of rotary dies; (d) a liquid fill system (medicine pump system); (e) a wedge for heating gelatine ribbons and feeding said fill; and (f) one or more microgranule or nanogranule feeders located on each side of the rotary dies, said feeders being synchronized to rotate at the same tangential speed as the rotary dies. | 03-08-2012 |
| 20120058180 | Liver-specific Nanocapsules and Methods of Using - This disclosure describes liver-specific nanocapsules for specifically targeting liver cells. This disclosure also provides methods of using such liver-specific nanocapsules to deliver one or more cargo moieties to the liver cells. | 03-08-2012 |
| 20120064152 | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same - The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of: | 03-15-2012 |
| 20120070492 | RHEIN OR DIACEREIN COMPOSITIONS - The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions. | 03-22-2012 |
| 20120070493 | TARGETED MULTI-EPITOPE DOSAGE FORMS FOR INDUCTION OF AN IMMUNE RESPONSE TO ANTIGENS - Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed. | 03-22-2012 |
| 20120076854 | CELLULAR COMPOSITIONS FOR USE IN THERAPY - The present invention provides a therapeutic composition comprising:
| 03-29-2012 |
| 20120082718 | Morphine Formulations - Described is a pellet composition comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a coating disposed on at least a portion of the core element, the coating comprising an insoluble matrix polymer which is insoluble at pH 1 to 7.5; an enteric polymer which is insoluble at pH 1 to 4 and soluble at pH 6 to 7.5; and an acid soluble polymer which is soluble at a pH of 1 to 4, wherein the ratio of the acid soluble polymer to the enteric polymer is 1.45:1 to 2.5:1 on a weight basis. Also described are dosage forms comprising the disclosed pellets. | 04-05-2012 |
| 20120093922 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. | 04-19-2012 |
| 20120093923 | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses, Or Conditions - A method and apparatus for delivering a plurality of medicaments in a single delivery vehicle for the management of co-morbid diseases, illnesses and conditions. The present invention provides a novel delivery process for many medicaments. Medicaments may be encapsulated and stored separately within a larger capsule until the time of ingestion, consumption, or the like. Benefits of the present invention include maintaining separation of distinct ingredients within a single capsule and the capability to control the time release of multiple ingredients within the capsule. | 04-19-2012 |
| 20120093924 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 04-19-2012 |
| 20120093925 | ORAL MEDICINAL COMPOSITION AND ORAL MEDICINAL CAPSULE HAVING THE COMPOSITION ENCAPSULATED THEREIN - The present invention relates to an oral medicinal composition comprising (a) a medical agent that is low in solubility in both water and oils but is soluble in a polyethylene glycol, (b) a polyethylene glycol that is solid at temperatures of 40° C. or lower, and (c) an oily or aqueous auxiliary agent. The oral medicinal composition cannot provide any stimulus or unpleasant feeling during being dissolved in the mouth, and is improved in the solubility of the medicinal agent in the mouth, and is also improved in the absorbability of the medicinal agent in the mouth. | 04-19-2012 |
| 20120107393 | Pellets for Delivery of Biologically Active Substances - Pellets are made by combining a direct compression binder and a waxy spheronizing agent. The pellets may further contain additional pharmaceutical ingredients and/or a drug. The pellets may be compressed to form tablets or loaded into a capsule shell for oral administration, and the pellets may or may not have an additional coating. | 05-03-2012 |
| 20120107394 | IMMUNO-COMPATIBLE HYDROGEL SYSTEM - An immuno-compatible hydrogel system is provided that is resistant to protein binding. The hydrogel system is prepared by contacting a hydrogel solution with a cross-linking agent to form a gel, exposing the gel to an aqueous solution comprising a first polyelectrolyte to form a polyelectrolyte-coated hydrogel, exposing the polyelectrolyte-coated hydrogel to a second polyelectrolyte to form a crosslinked matrix and exposing the matrix to conditions which eliminates, or at least reduces, protein binding sites on the matrix. | 05-03-2012 |
| 20120114747 | PHARMACEUTICAL-GRADE FERRIC ORGANIC COMPOUNDS, USES THEREOF AND METHOD OF MAKING SAME - The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels. | 05-10-2012 |
| 20120114748 | Tanaproget Compositions Containing Ethinyl Estradiol - Compositions containing micronized tanaproget, or a pharmaceutically acceptable salt thereof, and ethinyl estradiol and methods of preparing the same are provided. Also provided are kits containing the compositions, methods of contraception and hormone replacement therapy including administering a composition containing micronized tanaproget and ethinyl estradiol. | 05-10-2012 |
| 20120114749 | COMPOSITIONS AND METHODS FOR DELIVERY OF EMBOLICS - Described herein are compositions comprising one or more embolics attached to an inert, dissolvable matrix as well as kits comprising these novel embolic formulations. Also described are methods of making and using these embolic formulations. | 05-10-2012 |
| 20120121698 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. | 05-17-2012 |
| 20120121699 | LYCOPENE AND RESVERATROL DIETARY SUPPLEMENT - A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ≧95% purity and resveratrol is of ≧98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in crystal powder to optimize oral intake in the form of capsule or tablet. In small dosage, it should preferably include a minimum of 5 mg of lycopene and 10 mg of resveratrol. Various range of ratios of lycopene:resveratrol are provided for specific therapeutic purposes including 1:4 for symptomatic relief of arthritis, 1:2 for inhibiting melanoma or carcinoma malignancy, and 1:3 for inhibiting hyperlipoidemia. Generally, our dietary supplement composition may be used as an agent for anti-ageing, anti-oxidative, inhibiting cardiovascular diseases, relieving menopause symptoms and remission of post-operative cancer patients. | 05-17-2012 |
| 20120128764 | CONTROLLED-RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR - The present invention relates to pharmaceutical compositions, and methods of preparing such compositions, comprising one or more populations of controlled-release particles comprising one or more proton pump inhibitors. The present invention also relates to pharmaceutical dosage forms, including orally disintegrating tablets, tablets, capsules, and methods for their preparation. | 05-24-2012 |
| 20120128765 | METHOD AND DEVICE FOR PRODUCING SOFT CAPSULES - The claimed subject matter relates to a rotary die device for producing soft capsules, comprising a capsule forming unit for forming a soft-capsule shell and a dosing unit for feeding a filling material into the capsule forming unit, characterized in that the dosing unit comprises a conveying apparatus of viscous melts and a portioner, wherein the portioner is connected at an end thereof to the conveying apparatus of viscous melts and is arranged in a filling wedge with a section in such a way that filling material from the portioner reaches the location of the capsule filling directly or by means of one or more channels having a length of at most 30 mm. Using said device, high-viscosity filling materials can be filled and thus novel soft capsules can be made accessible. | 05-24-2012 |
| 20120128766 | Self-Breaking Tablets - Self-breaking core tablets and functionally coated tablets and capsule formulations are provided. Methods for production of these tablet and capsule formulations and their administration are also provided. | 05-24-2012 |
| 20120135069 | NANONIZED TESTOSTERON FORMULATIONS FOR IMPROVED BIOAVAILABILITY - Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral products on the market. The drug is dissolved in a melted lipid phase, which is subsequently nanonized. The drug is associated with the lipid. The drug can also be nanonized without having lipid present yielding nanocrystals. The nanonized drug can be incorporated into tablets or capsules for oral administration, typically one unit is sufficient for delivery of a single dose. | 05-31-2012 |
| 20120135070 | Copolymers - The invention provides a block copolypeptide comprising a hydrophilic heteropolypeptide block (A) and a hydrophobic homopolypeptide block (B). There is also provided a polymersome comprising a block copolypeptide of the invention. The invention further provides a method for preparing a copolymer comprising ring-opening polymerisation (ROP) of an amino acid N-carboxyanhydride (NCA) initiated from a peptide. | 05-31-2012 |
| 20120135071 | Abuse-proofed dosage form - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 05-31-2012 |
| 20120148669 | METHOD FOR PREPARING FUNCTIONALIZED LIPID CAPSULES - The present invention relates to a liquid lipid core/solid lipid shell capsule surface-functionalized with at least one compound containing at least one amino function, characterized in that the lipid core/lipid shell architecture is on the nanometric scale and in that said compound is covalently bonded to said solid lipid shell via a transacylation reaction. It also relates to a method for preparing such capsules. | 06-14-2012 |
| 20120148670 | SENSITIVE POLYMER CAPSULE AND METHOD OF MANUFACTURING THE SAME - A polymer capsule manufactured by polymerizing a compound represented by Formula 1, or polymerizing the compound of Formula 1 and a compound of Formula 2, wherein a detailed structure of the compounds of Formulae 1 and 2 is presented in the detailed description. | 06-14-2012 |
| 20120148671 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 06-14-2012 |
| 20120156285 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 06-21-2012 |
| 20120177727 | Method and Apparatus for the Preparation of Capsules - An apparatus for a continuous encapsulation process is provided. The apparatus is a vibrating tubing used alone, in series, or in combination with an encapsulation apparatus, which is used alone or in series. The vibrating tubing is a flat coil, a standing spiral, or a flume. The encapsulation apparatus includes a winding having coils disposed in an aqueous gelling solution. The winding is rotatable about its longitudinal center axis. The winding has adjacently spaced coils forming a plurality of chambers. Objects to be encapsulated are added to the apparatus such that when the winding is rotated, the chambers transport a volume of objects through the length winding in the aqueous gelling solution in a predetermined time. | 07-12-2012 |
| 20120177728 | OXALIPLATIN NANOPARTICLES AND METHOD FOR PREPARING SAME - The present invention relates to a nanoparticle of oxaliplatin, which is a water-soluble active substance, a pharmaceutical composition containing the same, and a method for preparing an orally administrable oxaliplatin nanoparticle by emulsifying a lipid mixture solution wherein a solid lipid and a surfactant are mixed in an aqueous mixture solution wherein oxaliplatin and a specific cosolvent are mixed and then removing the solid lipid and the cosolvent using a supercritical fluid gas. | 07-12-2012 |
| 20120177729 | SUSTAINED RELEASE COMPOSITION OF RANOLAZINE - The present invention relates to sustained release dosage form of Ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof which comprises a combination of at least two pH-dependent binders and optionally one or more pharmaceutically acceptable excipient(s). | 07-12-2012 |
| 20120183605 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo. | 07-19-2012 |
| 20120183606 | DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT - The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of polyoxazoline having a molar mass of at least | 07-19-2012 |
| 20120201875 | STABLE LOW DIGESTIVE ENZYME CONTENT FORMULATION - The present invention is directed to a pharmaceutical composition or dosage form having a stable, low (diluted) digestive enzyme content comprising at least one digestive enzyme and at least one carrier, or a dosage form thereof. The invention is also directed to a process of preparation of the composition or the dosage form. In addition the invention is directed to the treatment and prevention of disorders or conditions associated with a digestive enzyme deficiency in a patient in need thereof, comprising administering to said patient a pharmaceutically acceptable amount of the composition having a stable low digestive enzyme content or dosage form thereof. | 08-09-2012 |
| 20120207822 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE - Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with 3,3-dimethyl-1-butanol (DMB) and related compounds, and pharmaceutical formulations thereof. In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness. | 08-16-2012 |
| 20120207823 | PHARMACEUTICAL PELLETS COMPRISING MODIFIED STARCH AND THERAPEUTIC APPLICATIONS THEREFOR - Vaginal use compositions comprising pellets prepared from a debranched starch. Pellets may be conveniently prepared via extrusion/spheronization. | 08-16-2012 |
| 20120213846 | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug. | 08-23-2012 |
| 20120213847 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 08-23-2012 |
| 20120231072 | THERMO-RESPONSIVE HYDROGEL COMPOSITIONS - A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having an amino acid side chain. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nanoparticle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent. | 09-13-2012 |
| 20120237593 | Formulations of Guanylate Cyclase C Agonists and Methods of Use - The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative. | 09-20-2012 |
| 20120237594 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 09-20-2012 |
| 20120237595 | METHODS FOR TREATING AMYLOIDOSIS USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))- ISOINDOLINE-1,3-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 09-20-2012 |
| 20120237596 | NUTRIENT DELIVERY DRUG COMPOSITION - The present invention is a chemical composition that includes loratidine, a selected one or more of an expeller pressed and a cold pressed oil, a selected one or more of a non-genetically modified, a non-genetically engineered and a non-chemically treated starch and a selected one or more of a non-genetically modified, a non-genetically engineered and a non-chemically treated cellulose. The chemical composition can also include a vitamin E oil preservative and infused chili olive oil and is typically encased in a capsule. | 09-20-2012 |
| 20120237597 | METHOD FOR TREATING PSORIASIS - A method for treating psoriasis in a subject suffering from psoriasis comprising orally administering to the subject a pharmaceutically effective amount of crude | 09-20-2012 |
| 20120244214 | METHODS FOR TREATING MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH PROTEASOME INHIBITOR - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 09-27-2012 |
| 20120251621 | Nutritionally Enhanced Fraction From Rice Bran And Method of Lowering Insulin Resistance Using Same - Nutritionally enhanced nutraceutical Hydrophilic and Lipophilic Rice Bran Fractions from rice bran are provided, as well as a method of using the same to reduce Insulin Resistance in animals, especially humans with pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome. Provided in various example embodiments are mixtures of elevated levels of nutraceutical compounds, including but not limited to gamma-oryzanol, inositol, ferulic acid, tocotrienols and phytosterols and pharmaceutical and nutritional compositions thereof. Steps are provided including evaluating insulin resistance parameters, initiating therapy including providing therapeutic amounts of Hydrophilic and Lipophilic Rice Bran Fractions from rice bran to treat pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome, managing compliance with the therapy, and monitoring and reevaluating the therapy. | 10-04-2012 |
| 20120258166 | RIFAXIMIN COMPOSITIONS AND METHOD OF USE - Forms of rifaximin (INN) antibiotic, such as the poorly crystalline form named rifaximin γ are described, along with the production of medicinal preparations containing rifaximin for oral and topical use. | 10-11-2012 |
| 20120263785 | STABLE CANNABINOID COMPOSITIONS AND METHODS FOR MAKING AND STORING THEM - A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form. | 10-18-2012 |
| 20120269887 | POMEGRANATE FRUIT POLYPHENOL COMPOSITION AND METHODS OF USE AND MANUFACTURE THEREOF - A pharmaceutical composition with an active pharmaceutical ingredient including a pomegranate fruit polyphenol extract. The pomegranate fruit polyphenol extract includes at least about 3% combined punicalagin A and punicalagin B by weight, less than about 5% ellagic acid and their derivatives by weight, and less than about 1% anthocyanins by weight. | 10-25-2012 |
| 20120269888 | BARRIER COMPOSITION - The invention is directed to a barrier composition, to a vehicle comprising said barrier composition, to a layer comprising said barrier composition, to a foodstuff comprising said vehicle or layer, to a pharmaceutical or nutraceutical composition comprising said vehicle or layer, to a method for protecting one or more active ingredients, and to the use of said barrier composition. | 10-25-2012 |
| 20120269889 | NON-GELATIN SOFT CAPSULE SYSTEM - A non-gelatin encapsulation system for liquid filled soft capsules, by nature of the carrier, the cationic-ionic balance of the carrier and the active ingredients, or the concentration of the active ingredients and excipients, are difficult or impossible to commercially encapsulate in gelatin capsules. In particular, the system is adapted for the encapsulation of highly basic, or alkaline, fills. The system provides for a predominantly starch and gelling carrageenan based shell, which displays high resistance to both concentrated fills and to alkaline fills, in particular, to those fills which contain the salt or salts of weak acids and strong bases. | 10-25-2012 |
| 20120276194 | PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD AND USES THEREOF - The present invention relates to a pharmaceutical composition comprising micronized progesterone, soya bean lecithin, and at least one oil selected from the group consisting of sunflower oil, olive oil, sesame see oil, colza oil, almond oil, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion. | 11-01-2012 |
| 20120282330 | CHINESE HERBAL COMPOSITION FOR THE TREATMENT OF MACULAR DEGENERATION AND THE PROCESS FOR MANUFACTURING THE SAME - The present invention provides a Chinese herb composition for the treatment of macular degeneration and its preparation method. The composition comprises Salviae miltiorrhizae, Chuanxiong rhizoma, Lycii fructus, Chrysanthemi flos, Schisandrae chinensis fructus, Imperatae rhizoma, and Scutellariae radix, where the number of units by weight are: 0.8-3.0 units of Salviae miltiorrhizae, 0.3-2.0 units of Chuanxiong rhizoma, 0.6-2.4 units of Lycii fructus, 0.5-2.0 units of Chrysanthemi flos, 0.2-1.2 units of Schisandrae chinensis fructus, 0.9-6.0 units of Imperatae rhizoma, and 0.5-2.0 units of Scutellariae radix. The preparation method includes taking concentrated powder of each ingredient according to the number of units prescribed and mixing them together. The Chinese herb composition, conveniently delivered orally or parenterally, has been clinically proven to be safe and effective for all types of macular degeneration regardless of wet or dry forms. | 11-08-2012 |
| 20120282331 | MAMMALIAN METABOLITES OF STEROIDS - Described herein, in certain embodiments, are steroidal derivatives, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. | 11-08-2012 |
| 20120288559 | ORGANIC COMPOUNDS - The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator. | 11-15-2012 |
| 20120288560 | Methods for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 11-15-2012 |
| 20120294935 | PROCESS FOR THE PRECIPITATION AND ISOLATION OF 6,6-DIMETHYL-3-AZA-BICYCLO [3.1.0] HEXANE-AMIDE COMPOUNDS BY CONTROLLED PRECIPITATION AND PHARMACEUTICAL FORMULATIONS CONTAINING SAME - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 11-22-2012 |
| 20120308649 | Bacterial cellulose composite with capsules embedded therein and preparation thereof - A composite of bacterial cellulose and capsules embedded therein is prepared, for example calcium alginate capsules encapsulating functional components being discretely embedded in a matrix of | 12-06-2012 |
| 20120308650 | MODIFIED ALGINATES FOR CELL ENCAPSULATION AND CELL THERAPY - Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers. | 12-06-2012 |
| 20120308651 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF - Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided. | 12-06-2012 |
| 20120308652 | ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR - The invention relates to pharmaceutical formulations, preferably in the form of an oral dosage form, for the treatment of chronic hepatitis-B virus infections, containing micronised Entecavir, and processes for preparing it. The invention further relates to intermediates containing micronised entecavir, in which the D50 value for the particle size distribution is less than 50 μm, and processes for preparing them. | 12-06-2012 |
| 20120308653 | WORMWOOD PILL CONTAINING 95% OF WORMWOOD ETHYL ALCOHOL EXTRACT THAT HAS INACTIVATION EFFICACY OF THE H1N1 VIRUS AND THE H9N2 AVIAN INFLUENZA VIRUS - A mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is disclosed. In more details, the conventional mugwort pill is prepared by a hot water extraction method and has 0.8% of crude fat component; however the ethanol extract mugwort crude fat of the present invention is 11.6%, in particular the crude fat component is 14.5 times higher, and the novel swine-origin influenza virus (H1N1) can be inactivated 99.99%, and it has a good disinfection effect to an avian influenza virus (H9N2). When a mugwort pill containing a 95% ethanol extract of wormwood having an inactivation power with respect to a novel swine-origin influenza virus and an avian influenza virus is administrated to people or fowls, the people or fowls can have immunity with respect to a novel swine-origin influenza virus and an avian influenza virus. | 12-06-2012 |
| 20120315325 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 12-13-2012 |
| 20120315326 | MULTIPARTICULATE L-CARNITINE COMPOSITIONS AND RELATED METHODS - Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 12-13-2012 |
| 20120321702 | PHARMACEUTICAL COMPOSITION OF LANSOPRAZOLE - The invention refers to an oral solid pharmaceutical composition comprising a mixture of: (a) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof being free of alkaline-reacting compounds and (b) pellets comprising lansoprazole or a pharmaceutically acceptable salt thereof together with alkaline-reacting compounds. | 12-20-2012 |
| 20120321703 | CAPSULE FOR ORAL PET MEDICINE - A capsule for the administration of pet medicine is described. The capsule comprises a main hollow body containing a liquid ingredient and having the configuration of a pet treat for receiving and concealing therein a pet medicine. The liquid ingredient contained in the capsule, with the medicine therein, is configured to be frozen and orally ingested by the pet. A method of orally administering medicine to a pet is also described. | 12-20-2012 |
| 20120321704 | Compound sea Cucumber Product, Preparation Method, and Dosage Forms Thereof - A compound sea cucumber product, preparation method thereof and dosage forms thereof are disclosed. A fresh sea cucumber is cut open, the viscus thereof is taken out, and they are well-cleaned respectively and put into an airtight container; at 70˜130° C., gelatinate for 1 min˜20 hours; thereafter freeze-dry till the water content is less than 10 wt %; apply coarse crushing till the fineness reaches 10˜300 mesh; then apply ultra-micro crushing by means of an airflow crusher until the fineness reaches 100˜3000 mesh; lastly apply nanometer crushing by means of high-energy ball grinding mill till the fineness reaches 10˜1000 nm. The nanometer sea cucumber extract is mixed with panax pseudo-ginseng saponins extract at the proportion of 99˜80 wt %:1˜20 wt %. The compound preparation of nanometer sea cucumber and panax pseudo-ginseng saponins can greatly enhance the pharmacological functions of the sea cucumber single preparation or the panax pseudo-ginseng single preparation and eliminate the side effects of the single preparations when used alone. The compound preparation can achieve a better health-care effect than the single preparations and it can be applied for various health-care and medicinal purposes. | 12-20-2012 |
| 20120321705 | Lineage Restricted Glial Precursors from the Central Nervous System - A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5 | 12-20-2012 |
| 20120328695 | COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC FATIGUE - Pharmaceutical compositions and methods for the treatment of chronic fatigue in human patients comprising a central nervous system (CNS) stimulant in a daily low-dosage amount in combination with therapeutically effective daily amounts of micronutrients, comprising acetyl L-carnitine, L-tyrosine, N-acetyl cysteine, and alpha-lipoic acid. The CNS and micronutrient components may be in an oral dosage composition containing a low dosage amount of CNS stimulant such as about 2.5 mg methylphenidate HCl together with about 60-250 mg acetyl L-carnitine, 50-200 mg L-tyrosine, 60-250 mg N-acetyl cysteine, and 25-100 mg alpha-lipoic acid. | 12-27-2012 |
| 20120328696 | ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER - The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME). | 12-27-2012 |
| 20130004563 | MULTIPARTICULATE S-ADENOSYLMETHIONINE COMPOSITIONS AND RELATED METHODS - Multiparticulate compositions having S-adenosylmethionine an active ingredient are disclosed. The multiparticulates have spheroidal core comprising S-adenosylmethionine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. | 01-03-2013 |
| 20130004564 | ANTIMICROBIAL PEPTIDES - The present invention relates to novel peptides having antimicrobial activity, and compositions containing the same. | 01-03-2013 |
| 20130004565 | PROTEOLYTIC ENZYME FORMULATIONS - Preferred embodiments of the present invention relate to proteolytic enzyme formulations. More specifically, several embodiments relate to a proteolytic formulation to facilitate digestion, metabolism, degradation of target compounds, and systemic enzymatic action. Embodiments for improving oxygenation and reducing plaque are also provided. | 01-03-2013 |
| 20130004566 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 01-03-2013 |
| 20130004567 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 01-03-2013 |
| 20130004568 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 01-03-2013 |
| 20130004569 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 01-03-2013 |
| 20130011468 | FATTY ACID COMPOSITION FOR TREATMENT OF ALZHEIMER'S DISEASE AND COGNITIVE DYSFUNCTION - This invention relates to the use of a fatty acid composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, and (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof for manufacturing of a medicinal product or a food stuff for the treatment and/or prevention of amyloidos-related diseases, such as Alzheimer's disease, as well as treatment/prevention of cognitive dysfunction. | 01-10-2013 |
| 20130017254 | PHARMACEUTICAL FORMULATION CONTAINING PHENYTOIN SODIUM AND MAGNESIUM STEARATE - The present invention relates to a novel pharmaceutical formulation comprising phenytoin sodium, a high amount of magnesium stearate, and a low level of a hydrophilic polymer such as a methocel, and a method of preparing the same by blending. | 01-17-2013 |
| 20130017255 | Tamper Resistant Dosage Form Comprising an Adsorbent and an Adverse Agent - Pharmaceutical compositions and dosage forms comprising an adsorbent, and an adverse agent, such as an opioid antagonist. In one embodiment, at least a portion of the adverse agent is on the surface or within the micropore structure of an adsorbent material. The pharmaceutical compositions and dosage forms comprising the adsorbent and the adverse agent are useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods for treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient. The present invention further relates to process for preparing such pharmaceutical compositions and dosage forms. | 01-17-2013 |
| 20130017256 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 01-17-2013 |
| 20130022670 | Aqueous Pharmaceutical Formulation of Tapentadol for Oral Administration - An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives. | 01-24-2013 |
| 20130022671 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR - Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided. | 01-24-2013 |
| 20130022672 | Stabilized Amorphous Forms of Imatinib Mesylate - The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions. | 01-24-2013 |
| 20130022673 | ENHANCEMENT OF MAGNESIUM UPTAKE IN MAMMALS - Disclosed are methods and complexes for increasing magnesium uptake in mammals. Increasing magnesium uptake in mammals is accomplished by concurrently administering one or more magnesium salts with one or more quaternary amines and/or phosphatides and one or more di- or tri-carboxylic acids, in a one part dosage system or a multi-part dosage system. Increasing magnesium uptake in mammals may also be accomplished by concurrently administering one or more magnesium salts with an organic acid. | 01-24-2013 |
| 20130028968 | COMPOSITIONS AND METHODS TO RELIEVE CHRONIC DISEASES SYMPTOMS - Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera | 01-31-2013 |
| 20130034600 | PEPTIDE PHARMACEUTICAL OF ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 02-07-2013 |
| 20130034601 | METHOD FOR INCREASING LACTOSE TOLERANCE IN MAMMALS EXHIBITING LACTOSE INTOLERANCE - The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely. | 02-07-2013 |
| 20130045273 | METHODS FOR USING NUTRITIONAL SUPPLEMENTS CONTAINING LIPOIC ACIDS AND SULFUR CONTAINING COMPOUNDS - Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds to maintain or increase the levels of cellular GSH in the body are described. In some instances, the nutritional supplements can increase both the levels of GSH, vitamin C, GST activity, and antioxidant protection in the blood. The nutritional supplement contain a first part containing an effective amount of a lipoic acid and a second part containing an effective amount of a sulfur containing compound that increases the level of GSH vitamin C, GST activity, and antioxidant protection in the blood The first part and second part of the nutritional supplement can be partially or completely separated. The increased GSH and vitamin C levels increases the detoxification ability of the body as measured by the GST (Glutathione S-Transferases) activity and the antioxidant protection as measured by SAR (Serum Antioxidant Reserve). Other embodiments are described. | 02-21-2013 |
| 20130045274 | BACTERIOTHERAPY FOR CLOSTRIDIUM DIFFICILE COLITIS - This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota. | 02-21-2013 |
| 20130045275 | SUSTAINED-RELEASE CHITOSAN CAPSULES COMPRISING CHITOSAN AND PHYTIC ACID - The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material. Further, since the capsule of the present invention has a pH-dependent sustained-release mechanism which can minimize the release of a soluble active ingredient in the stomach and gradually release in the intestine, it is possible to regulate sustained-release of a soluble active ingredient. | 02-21-2013 |
| 20130071472 | Fascile synthesis of biocompatible polymer capsule nanoparticles for drug encapsulation - The present invention relates to a method for preparing a capsule nanoparticle used in encapsulating hydrophobic medicines, comprising the following steps: (A) providing a biocompatible polymer and an organic solution containing a hydrophobic medicine; (B) stirring the organic solution at 3-10° C., and titrating with an alcohol solution, so as to make the biocompatible polymer encapsulate hydrophobic medicine to form a capsule nanoparticle; (C) ultrasonic vibrating the capsule nanoparticle at 3-10° C.; (D) filtering the capsule nanoparticle to an average size controllable in the range of 60-450 nm; and (E) lyophilizing the encapsulated particles. | 03-21-2013 |
| 20130089602 | ENCAPSULATED CHELATOR - An enhanced chelator includes a chelating agent and a volatile material encapsulated in a biologically benign microcapsule. The enhanced chelator possesses significantly improved shelf-life in aqueous biological buffer solutions because the chelating agent is encapsulated in the microcapsule and, therefore, separated from solution components with which the chelating agent would react. The enhanced chelator is activated at a predetermined elevated temperature defined by the boiling point of the volatile material. At this predetermined elevated temperature, the volatile material exerts a vapor pressure sufficient to rupture the microcapsule and thereby release the chelating agent from the microcapsule. In one embodiment, a manganese chelator such as ethylene glycol tetraacetic acid (EGTA) is solubilized in ethanol and encapsulated in a poly(lactic-co-glycolide) (PLGA) microsphere. Upon heating to 80° C., ethanol boils within the PLGA microsphere and undergoes several orders of magnitude volume change, thereby rupturing the PLGA microsphere and releasing EGTA. | 04-11-2013 |
| 20130089603 | COMPOSITIONS AND METHODS FOR TREATING OBESITY AND OBESITY-RELATED CONDITIONS - A method to effectively treat the adverse events of ingested lipase inhibitor such as orlistat, and to maintain the effectiveness of ingested orlistat, the method comprising the steps of: ingesting a compound of orlistat to irreversibly bind with lipase enzymes of the gastrointestinal tract; ingesting a compound of simethicone to cause undigested fats to remain in an emulsified state in the bowel; and ingesting an enteric-coated activated charcoal to absorb emulsified fats only in the lower bowel, thus preventing the adverse events associated with the ingestion of orlistat alone. | 04-11-2013 |
| 20130095176 | CONTROLLED RELEASE DRUG DELIVERY COMPOSTION - A controlled release delivery composition comprising: a housing adapted for oral administration; and a plurality of discrete vehicles assembled within the housing, each of the vehicles are not compressed together, each of the vehicles being a bead, a pellet, a tablet, and/or granules compressed into a preselect shape, wherein each of the vehicles comprise a different combination and/or amount of an active agent, an amino acid, a buffer, and a polymer, such that each of the vehicles comprises a different active agent and/or release property from each other, wherein each of the vehicles releases the active agent independently of each other, and wherein each of the vehicles remains independent from each other and intact within the housing prior to oral administration of the delivery composition. | 04-18-2013 |
| 20130101668 | TRANSITION METAL MEDIATED OXIDATION OF HETERO ATOMS IN ORGANIC MOLECULES COORDINATED TO TRANSITION METALS: OXIDATION OF COORDINATED BENZIMIDAZOLE TO OMEPRAZOLE - The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl) methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to the sulfoxide commonly known as omeprazole and wherein one of either the R and S enantiomers is formed to an enantiomeric excess. | 04-25-2013 |
| 20130115280 | PHARMACEUTICAL AND/OR DIETARY COMPOSITIONS BASED ON SORT CHAIN FATTY ACIDS - Pharmaceutical and/or dietary compositions based on short chain fatty acids or salts, esters and/or amides thereof in combination with one or more dietary soluble or water-dispersible fibre and at least one flavouring agent are disclosed. | 05-09-2013 |
| 20130122085 | PHARMACEUTICAL COMPOSITIONS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF - This invention provides a pharmaceutical composition comprising Compound I-V, including inter alia solid dosage forms of powder-filled capsule formulations, liquid-filled softgel capsules (softgels), tablets, and sustained release dosage forms, and uses thereof in treating a variety of diseases or conditions in a subject, for example, treating a muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others. | 05-16-2013 |
| 20130129818 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 05-23-2013 |
| 20130136791 | MULTI-PHASE, MULT-COMPARTMENT CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 05-30-2013 |
| 20130142869 | Compositions Comprising Non Steroidal Anti-inflammatory Drugs and Methods for Use Thereof - The invention provides analgesic, antipyretic and anti-inflammatory compositions containing epilactose in combination with non-steroidal anti-inflammatory drugs and pharmaceutically acceptable zinc compounds. This invention relates to the use of these novel compositions for significantly improved and synergistic safety and therapeutic profiles. | 06-06-2013 |
| 20130142870 | NERAMEXANE MULTIPLE UNIT DOSAGE FORM - Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm. | 06-06-2013 |
| 20130149377 | CUSTOM-PILL COMPOUNDING SYSTEM WITH FILLER-FREE CAPABILITY - A system and associated aspects thereof are disclosed regarding custom-compounding of drug products such as pills and polypills for particular patients, herein involving adaptations of “micro-dosing” technology to permit sufficiently small and precise amounts of drug substances or optionally formulations thereof to be controllably and automatably handled and dispensed so as to help create customized drug products that do not necessitate bulking or dilution of the drug substances. | 06-13-2013 |
| 20130156852 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 06-20-2013 |
| 20130156853 | Liquid Compositions of Insoluble Drugs and Preparation Methods Thereof - A liquid composition of an insoluble medicament and a preparation method thereof are disclosed. The composition includes insoluble medicament, oil for injection, phospholipid, and solvent; the percentage by weight of each component is as follows: insoluble medicament 0.01-10%, oil for injection 0%-20%, phospholipid 10-80%, solvent 20-89%. The preparation method for the composition includes the following steps: dissolving an insoluble medicament into solvent or oil for injection or a mixture thereof firstly, and then adding other components, and mixing uniformly; or dissolving an insoluble medicament into a mixture of other components, and mixing uniformly; or dissolving an insoluble medicament into part of solvent firstly, and then adding into a mixed solvent of other components and the remaining solvent, and mixing uniformly. | 06-20-2013 |
| 20130164371 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 06-27-2013 |
| 20130164372 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 06-27-2013 |
| 20130164373 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 06-27-2013 |
| 20130164374 | REDUCTION IN BACTERIAL COLONIZATION BY ADMINISTERING BACTERIOPHAGE COMPOSITIONS - The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage. | 06-27-2013 |
| 20130164375 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof | 06-27-2013 |
| 20130171244 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-04-2013 |
| 20130171245 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-04-2013 |
| 20130171246 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-04-2013 |
| 20130171247 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-04-2013 |
| 20130171248 | ORAL FORMULATION FOR DELIVERY OF POORLY ABSORBED DRUGS - A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone). | 07-04-2013 |
| 20130171249 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 07-04-2013 |
| 20130171250 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 07-04-2013 |
| 20130171251 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 07-04-2013 |
| 20130171252 | Formulation Comprising a Type B Lantibiotic - Described is a pharmaceutical formulation of a capsule for oral delivery of a type B lantibiotic to the stomach comprising a hard gelatine, HPMC or starch capsule, and a type B lantibiotic of formula (I): wherein X is —NH(CH | 07-04-2013 |
| 20130177641 | COMPOSITIONS AND METHODS FOR DELIVERY OF HIGH-AFFINITY OXYGEN BINDING AGENTS TO TUMORS - While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body. | 07-11-2013 |
| 20130177642 | METHODS FOR TREATING MULTIPLE MYELOMA WITH 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 07-11-2013 |
| 20130183380 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-yl)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate - Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. | 07-18-2013 |
| 20130183381 | METHODS FOR TREATING MULTIPLE MYELOMA USING 4-(AMINO)-2-(2,6-DIOXO(3-PIPERIDYL))-ISOINDOLINE-1,3-DIONE IN COMBINATION WITH PROTEASOME INHIBITOR - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 07-18-2013 |
| 20130189353 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 07-25-2013 |
| 20130189354 | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy - The present invention relates to compositions and methods for treating pain wherein the compositions comprise a combination of tramadol or a pharmaceutically acceptable salt thereof, magnesium or a pharmaceutically acceptable salt thereof; and gabapentin or pregabalin. The therapeutic combination can further contain capsaicin or an ester of capsaicin. | 07-25-2013 |
| 20130195970 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 08-01-2013 |
| 20130195971 | PHARMACEUTICAL COMPOSITION 271 - The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions. | 08-01-2013 |
| 20130195972 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. | 08-01-2013 |
| 20130202688 | DELAYED RELEASE ORAL DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF LANSOPRAZOLE - The present invention relates to delayed release oral disintegrating pharmaceutical compositions of lansoprazole or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such compositions. | 08-08-2013 |
| 20130202689 | NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS - A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid. | 08-08-2013 |
| 20130216615 | Pharmaceutical Compositions Containing Dimethyl Fumarate - Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. | 08-22-2013 |
| 20130216616 | CUSTOMIZED POLYPILLS HAVING HIGH DRUG LOADS - Patient-specific polypills, or similar drug products with potential to benefit from reduced need for bulking agent and preferably having multiple active ingredients, producible via appropriately adapted “micro-dosing” technologies not requiring fluid-jet or like substrate and solvent dependent approaches, having less need for excipient, particularly filler, so that the products may contain a larger number of different drug substances having a lower overall number or amount of excipient materials and/or may contain drug substances having comparatively less need for formulation development or pre-production processing and/or may contain fewer potential causes of side effects. | 08-22-2013 |
| 20130224288 | F, G, H, I and K Crystal Forms of Imatinib Mesylate - The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their use as an intermediate or for the preparation of pharmaceutical preparations for use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, especially humans. | 08-29-2013 |
| 20130224289 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 08-29-2013 |
| 20130230585 | PHARMACEUTICAL COMPOUNDS - Provided herein is a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent and, as an active ingredient, the compound 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine bismesylate. | 09-05-2013 |
| 20130236538 | PHARMACEUTICAL COMPOSITIONS OF IBUPROFEN AND FAMOTIDINE - Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. In some embodiments, the ibuprofen is in direct physical contact with the famotidine. | 09-12-2013 |
| 20130243851 | EXTRUSION ENCAPSULATION OF ACTIVES AT AN INCREASED LOAD, USING SURFACE ACTIVE PLANT - A glassy extrusion encapsulation composition and a method of making the composition are provided. The encapsulation composition comprises an encapsulate encapsulated in a glassy matrix comprising 0.5 to 12% by weight, based on the total weight of the glassy matrix, of at least one surface active plant extract, and 88 to 99.5% of at least one carbohydrate. The addition of a surface active plant extract to a carbohydrate matrix markedly increases the load of an encapsulate in the encapsulation composition. Such glassy matrices are useful for encapsulation of encapsulates, for example, flavors and medications. A food composition containing the encapsulation composition is also provided. | 09-19-2013 |
| 20130243852 | ADJUVANT COMPOSITIONS AND METHODS OF POTENTIATING HDAC INHIBITORS USED TO TREAT VARIOUS DISEASES - A composition and method for potentiating, sensitizing, and/or amplifying at least one HDAC inhibitor targeting at least one disease in a patient is provided. In one embodiment, the composition is administered to potentiate, sensitize and/or amplify an HDAC inhibitor targeting at least one cancer. | 09-19-2013 |
| 20130251790 | Low Dose Pharmaceutical Composition Comprising Zanamivir - The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamivir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose. | 09-26-2013 |
| 20130259930 | Compositions and Methods for Preventing and Treating Mucositis and Weight Loss - Pharmaceutical compositions comprising 5-[2-pyrazinyl]-4-methyl-1,2-3-thione or an analogue, derivative, metabolite, prodrug, solvate or a pharmaceutically acceptable salt thereof; and a pharmaceutical carrier, which promotes association with the outer wall of a subject's digestive tract are described as well as their uses in treating and preventing mucositis and cachexia. | 10-03-2013 |
| 20130266642 | MALODOR REDUCTION COMPOSITIONS - The present invention relates to unscented and low scented malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. | 10-10-2013 |
| 20130266643 | Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis - Described herein are compositions comprising glyceryl-triacetate (GTA) for use in delivering non-glucose energy deriving metabolites during physical performance, which reduce lactate production and serve as thermogenic agents. | 10-10-2013 |
| 20130266644 | SENSOR - The present invention relates to a scaffolded sensor with a container comprising a drug for triggering drug release, wherein the scaffold is intrinsically conformationally metastable and a method to its manufacture. | 10-10-2013 |
| 20130280323 | Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture - Disclosed herein is a soft elastic capsule that includes an acid resistant, capsule shell that defines an encapsulated space having a predetermined volume, a liquid or semisolid fill comprising a first active ingredient located within the encapsulated space, and a first compressed tablet a having a minimal dimension of 2 mm, being located within the encapsulated space, unanchored to the capsule shell, and surrounded by the fill, said tablet comprising a second active ingredient that is substantially insoluble in the fill. A method of manufacturing a soft elastic capsule is also disclosed. | 10-24-2013 |
| 20130287840 | Bulk Enteric Capsule Shells - The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith. | 10-31-2013 |
| 20130287841 | Drug with Activity against the Herpes Virus Family - The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: | 10-31-2013 |
| 20130287842 | Hard Capsules - Publicly available pullulan hard capsule shells present certain drawbacks, notably a non fully satisfactory shell mechanical strength (i.e. shell brittleness) at shell low LOD. Improving this property is a particularly desirable goal for pullulan hard capsule shells. The present invention solves this and other objects by providing new hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules. | 10-31-2013 |
| 20130295168 | Oral Drug Delivery System - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 11-07-2013 |
| 20130295169 | Pharmaceutical Compositions Containing Dimethyl Fumarate - Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w. | 11-07-2013 |
| 20130302409 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY - The present invention generally relates to the field of cancer and methods and compositions for cancer immunotherapy. In one embodiment, a method for treating cancer in a patient comprises the steps of (a) administering at or near the cancer site an effective amount of a composition that promotes a therapeutic immune response to the cancer; and (b) ablating the cancer. In another embodiment, a method for treating an abnormal cellular proliferation in a patient comprises the steps of (a) administering at or near the site of the abnormal cellular proliferation an effective amount of a composition that promotes a therapeutic immune response to the abnormal cellular proliferation comprising (i) a polymeric particle; and (ii) optionally one or more therapeutic agents encapsulated in or incorporated on or into the polymeric particle; and (b) ablating the abnormal cellular proliferation. | 11-14-2013 |
| 20130302410 | Neuroprotection in Demyelinating Diseases - Methods of treating neurological disorders characterized by extensive demyelination and/or axonal loss are provided. Examples of such disorders include secondary progressive multiple sclerosis and Devic's disease. The disclosed methods include administering to a subject having such a disorder a therapeutically effective amount of, for example, dimethyl fumarate or monomethyl fumarate. | 11-14-2013 |
| 20130302411 | Agent for use in the case of fructose intolerance - There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed. | 11-14-2013 |
| 20130302412 | Transfer Factor Compositions - Compositions containing therapeutically effective amounts of transfer factor and one or more compounds selected from glucosamine salts, dimethyl glycine, chondroitin, montmoril-lonite, curcumin, hyaluronic acid, boswellic acid, superoxide dismutase, methyl sulfonyl methane and glucans. Methods of treating inflammation and arthritis with the compositions of the present invention are also disclosed. | 11-14-2013 |
| 20130302413 | POLYNUCLEAR MICROCAPSULES - A process is disclosed for preparing polynuclear microcapsules by polymerizing an alkoxysilane at the oil/water interface of a multiple phase emulsion to form a suspension of polynuclear microcapsules. Also disclosed are polynuclear microcapsules optionally comprising a hydrophilic active and uses thereof. | 11-14-2013 |
| 20130302414 | SOLUBILIZED CAPSULE FORMULATION OF 1,1-DIMETHYLETHYL [(1S)-1-CARBAMOYL)PYRROLIDIN-1-YL]CARBONYL}-2,2-DIMETHYLPROPYL]CARBAMATE - The present disclosure includes various embodiments directed to a solubilized capsule formulation of asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods including asunaprevir. | 11-14-2013 |
| 20130302415 | Pharmaceutical Composition - A pharmaceutical composition comprising efavirenz wherein the efavirenz is in the form of nanoparticles is disclosed. | 11-14-2013 |
| 20130315988 | Pharmaceutical Composition - A composition comprising rifaximin in the form of particles, wherein substantially all the particles have a particle size less than or equal to 2 micrometres. | 11-28-2013 |
| 20130315989 | METHOD FOR TREATING A PATIENT VIA PHOTODYNAMIC THERAPY COMPRISING A MACROMOLECULAR CAPSULE - A composition for photodynamic therapy including a polymer capsule having a diameter of about | 11-28-2013 |
| 20130315990 | DISIALYLLACTO-N-TETRAOSE (DSLNT) OR VARIANTS, ISOMERS, ANALOGS AND DERIVATIVES THEREOF TO PREVENT OR INHIBIT BOWEL DISEASE - The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof. | 11-28-2013 |
| 20130330404 | Extended release composition containing tramadol - An oral tramadol pharmaceutical composition for once daily administration, containing an effective amount of tramadol or a pharmaceutically-acceptable salt thereof, providing in vivo, a time of tramadol peak plasma concentration (T | 12-12-2013 |
| 20130337052 | System and Method of Reducing Impairment of Alertness, Concentration, Motivation, and Creativity Caused by Medication - Administering a therapeutically effective dose of lithium ions mitigates the side effects of a psychoactive substance such as a cannabinoid. The therapeutically effective dose of lithium ions includes greater than 4 milligrams of lithium and less than 170 milligrams of lithium, or includes between 8 and 32 milligrams of lithium ions per milligram of the psychoactive substance. The therapeutically effective dose of lithium ions is administered using lithium carbonate, lithium citrate, lithium chloride, lithium orotate, lithium aspartate, or analogs thereof using a delivery vehicle selected from pills, tablets, capsules, gelcaps, liquids, syrups, injectable liquids, powders, or foods and administered prior to, with, or after administration of the psychoactive substance. The psychoactive substance includes one or more of anandamide, 2-arachidonoyl glycerol, 2-arachidonoyl glycerol ether, tetrahydrocannabinol, cannabinol, cannabidiol, or analogs thereof and may be administered using the delivery vehicle. | 12-19-2013 |
| 20130337053 | NOVEL FORMULATIONS AND METHODS - A formulation comprising T3/VIP nanoparticles, wherein the T3/VIP nanoparticle comprises both T3 and VIP encapsulated or immobilized on a bioabsorbable polymer. The invention further provides for methods of making a formulation comprising a T3/VIP nanoparticle. The invention further provides for methods of treatment utilizing said T3/VIP nanoparticle. | 12-19-2013 |
| 20130337054 | TREATMENT OF EXCESSIVE MENSTRUAL BLOOD LOSS BY INTRAVAGINAL ADMINISTRATION OF LOW DOSES OF ANTIFIBRINOLYTIC OR HEMOSTATIC AGENT - A method and drug delivery device for reducing menstrual blood loss in a female are provided. The method comprises administering intravaginally to the female a therapeutically effective amount of an active agent on a delivery device directly to uterine cavity during a menstrual period, wherein the active agent is any one of an antifibrinolytic agent and a hemostatic agent. | 12-19-2013 |
| 20130337055 | COMPOSITIONS, METHODS OF TREATMENT AND DIAGNOSTICS FOR TREATMENT OF HEPATIC STEATOSIS ALONE OR IN COMBINATION WITH A HEPATITIS C VIRUS INFECTION - The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions. | 12-19-2013 |
| 20130337056 | COATED SOLID PHARMACEUTICAL PREPARATION - The invention is directed to coated solid pharmaceutical preparations having a very thin coating in the nanometer range and a method for producing such preparations. The coated solid pharmaceutical preparation can be prepared by using atomic layer deposition (ALD). | 12-19-2013 |
| 20130344140 | NOVEL PHARMACEUTICAL COMBINATIONS AND METHODS FOR TREATING CANCER - Methods of selectively targeting a p53-deficient cancer cell, comprising administering to a patient suffering from cancer (i) a reversible cell cycle arrest-inducing agent for inducing cell cycle arrest in a p53-positive cell; and (ii) an aurora kinase inhibitor, wherein said reversible cell cycle arrest-inducing agent is administered prior to administration of said aurora kinase inhibitor, and pharmaceutical combinations, kits and oral dosage forms for the same. | 12-26-2013 |
| 20140004182 | METHODS FOR THE TREATMENT OF SARCOIDOSIS | 01-02-2014 |
| 20140004183 | METHODS FOR TREATING CARDIOVASCULAR DISEASE IN STATIN-TOLERANT SUBJECTS | 01-02-2014 |
| 20140004184 | COATED TABLET FORMULATIONS AND USES THEREOF | 01-02-2014 |
| 20140010868 | KRILL OIL AND CAROTENOID COMPOSITION, ASSOCIATED METHOD AND DELIVERY SYSTEM - A medicine delivery system includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S,S′-astaxanthin derived from | 01-09-2014 |
| 20140017303 | ACCORDION PILL COMPRISING LEVODOPA FOR AN IMPROVED TREATMENT OF PARKINSON'S DISEASE SYMPTOMS - The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period. | 01-16-2014 |
| 20140017304 | METHOD FOR ENCAPSULATED THERAPEUTIC PRODUCTS AND USES THEREOF - The current invention relates to encapsulation methods comprising alginate-based microencapsulation for the immune-protection and long-term functioning of biological material or therapeutics. The biological material or the therapeutics are encompassed by a membrane formed by jellifying an alginate polymer. Specifically, although by no means exclusively, the encapsulation system is intended for use in allo-or xenotransplantation. The membrane provides for a protective barrier of the encapsulated material, ensuring the longevity and preventing unwanted influences from outside the barrier, such as inflammatory reactions or immune-responses. The invention is furthermore directed to methods of producing and providing the encapsulated products for use in cell therapies. The therapeutic products obtained by the encapsulation method may provide a method for ameliorating of treating a range of conditions. | 01-16-2014 |
| 20140017305 | ENCAPSULATED LIVER CELL COMPOSITION - Microcapsules including a capsule shell encapsulating a suspension of a therapeutically effective amount of liver cells in physical contact with a liver cell stimulating amount of erythropoietin. | 01-16-2014 |
| 20140017306 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 01-16-2014 |
| 20140017307 | LIQUID LAUNDRY DETERGENTS WITH PERFUME CAPSULES - The present invention relates to a structured liquid composition comprising anionic surfactant, nonionic surfactant and a plurality of stable and evenly suspended encapsulated actives. The liquid composition is externally structured by incorporating a cross-linked acrylic copolymer. | 01-16-2014 |
| 20140023702 | METHOD OF TREATING RETINITIS PIGMENTOSA - Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude | 01-23-2014 |
| 20140037719 | STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR - Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach. | 02-06-2014 |
| 20140037720 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The invention relates to a method of treating a subject in need of treatment for multiple sclerosis including orally administering to the subject in need thereof a delayed release pharmaceutical composition using an increasing dose regimen, wherein an initial daily amount of drug administered is increased later to a higher daily amount and the pharmaceutical composition consists essentially of (a) dimethylfumarate and (b) one or more pharmaceutically acceptable excipients. | 02-06-2014 |
| 20140037721 | Pharmaceutical Composition - Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated. | 02-06-2014 |
| 20140050782 | Layered Bodies, Compositions Containing Them and Processes for Producing Them - A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 μm or less. | 02-20-2014 |
| 20140050783 | METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS - Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations. | 02-20-2014 |
| 20140056973 | Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug - Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed. | 02-27-2014 |
| 20140056974 | Spontaneously Dispersible N-Benzoyl Staurosporine Compositions - Spontaneously dispersible N-benzoyl-staurosporine compositions are discussed for oral administration having high bioavailability levels and reduced variability of bioavailability levels of N-benzoyl-staurosporine, as well as their preparation and use in medical treatment. | 02-27-2014 |
| 20140056975 | Pharmaceutical Composition - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 02-27-2014 |
| 20140065210 | PROTEIN STABILIZED PROBIOTICS AND PERSONAL CARE PRODUCTS - The present invention relates to a personal care product comprising a protein matrix wherein said protein matrix comprises at least one protein, at least one probiotic and a carrier fluid. | 03-06-2014 |
| 20140072623 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 03-13-2014 |
| 20140072624 | UNIT DOSE FORM FOR ORAL ADMINISTRATION - Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer. | 03-13-2014 |
| 20140079775 | AGENTS TO TREAT/PREVENT AMOEBIASIS - The invention provides formulations comprising isolated lacto-N-tetraose (LNT) or galactooligosaccharides (GOS) or variants, isomers, analogs and derivatives thereof and a pharmaceutically acceptable carrier. | 03-20-2014 |
| 20140079776 | Nanostructures for Drug Delivery - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor. | 03-20-2014 |
| 20140079777 | DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS - Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided. | 03-20-2014 |
| 20140086986 | CAPSICUM VARIETY EXHIBITING A HYPER-ACCUMULATION OF ZEAXANTHIN AND PRODUCTS DERIVED THEREFROM - The present invention is concerned with | 03-27-2014 |
| 20140093559 | ABUSE-PROOFED DOSAGE FORM - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 04-03-2014 |
| 20140093560 | METHODS AND MATERIALS FOR THE TREATMENT OF TESTOSTERONE DEFICIENCY IN MEN - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism. | 04-03-2014 |
| 20140099360 | Gas Storage Vessel, Hydrogen-Charging Method, and Hydrogen-Charging Apparatus - The present invention relates to a technique for delivering gases into the human body or generating gases inside the human body, such as a method for encapsulating gases and a gas storage vessel. The present invention relates to a gas storage capsule and to a method for producing the gas storage capsule, wherein the capsule is dissolved in water such that the air-tightness thereof is gradually degraded and the gas contained in the capsule can be gradually leaked to the outside of the capsule. The present invention also relates to a hydrogen-generating material which directly generates hydrogen gases in vivo, and to a hydrogen-generating candy for directly encapsulating hydrogen using the material and delivering the thus-encapsulated hydrogen into the intestines, as well as to a method for producing the candy. | 04-10-2014 |
| 20140105970 | ADJUVANT AND ANTIGEN PARTICLE FORMULATION - A composition as disclosed is comprised of a plurality of particles and a pharmaceutically acceptable carrier. The particles are comprised of (1) an adjuvant; (2) a biocompatible polymer which maybe a co-polymer such as PLGA, and (3) a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. The carrier includes an adjuvant such as a monophosphoryl lipid A (MPL) different from the adjuvant in the particles. The particles may be sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell. | 04-17-2014 |
| 20140105971 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA IN HYPERCALCEMIC PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without removing calcium from the patient's body. Also disclosed are methods of using calcium-free or low calcium microporous zirconium silicate compositions for the treatment of hyperkalemia in patients also suffering from hypercalcemia. | 04-17-2014 |
| 20140105972 | PREVOTELLA HISTICOLA PREPARATIONS AND THE TREATMENT OF AUTOIMMUNE CONDITIONS - This document provides methods and materials related to | 04-17-2014 |
| 20140120161 | VECTOR FOR ORAL ADMINISTRATION - A vector for the oral administration of at least one pharmacologically active substance enabling the active substance to move from the intestinal lumen to the blood, optionally via interstitial liquid, without any substantial degradation of the substance, includes an essentially hydrophilic matrix having an outer surface which is modified by one or several chemical species providing the vector with an essentially lipophilic quality and containing one or several active substances. The vector is associated with a gastroresistant vehicle enabling it to pass into the stomach without any denaturation and/or degradation of the active substance. The invention also relates to pharmaceutical compositions containing the vector. The vectors can be used to produce medicaments used in human or veterinary medicine. | 05-01-2014 |
| 20140127289 | LOW ERUCTATION COMPOSITION AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT WITH FISH ALLERGY/HYPERSENSITIVITY - In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. | 05-08-2014 |
| 20140127290 | Microcapsules Encapsulating Living Cells - Disclosed are devices and methods for encapsulating living cells, microencapsulated cells produced by the disclosed devices and methods, as well as methods of using the disclosed microencapsulated cells. | 05-08-2014 |
| 20140134240 | pH INDUCED SILK GELS AND USES THEREOF - This invention provides for compositions, methods and devices for rapidly converting silk fibroin solution into a silk fibroin gel using direct application of voltage, in a process called electrogelation. The silk fibroin gel may be reversibly converted back to liquid form by applying reverse voltage or may be converted further to β-sheet structure by applying shear force or other treatments. The electrogelated silk may be used as an extracted bulk gel, spray or stream of gel for processing into materials or devices, or may be used as silk gel coating to devices. Active agents may be embedded in the silk gel for various medical applications. This invention also provides for methods and compositions for preparing adhesive silk pH-gels. For example, the method comprises reducing pH level of a silk fibroin solution to increase the bulk or local proton concentration of the silk fibroin solution, thereby forming adhesive silk gels. | 05-15-2014 |
| 20140134241 | TCR Mimic Antibodies as Vascular Targeting Tools - The present invention includes a method of delivering a therapeutic agent into and across an endothelial cell (EC) in a subject in need thereof, comprising: identifying a subject in need for treatment of a cancer in the brain; attaching to a TCR mimic an active agent to form a therapeutic agent; and administering to the subject the therapeutic agent in a pharmaceutically acceptable carrier, wherein the therapeutic agent effectively crosses the blood-central nervous system microvascular barrier. | 05-15-2014 |
| 20140141073 | ANTI-VIRUS HYDROPHILIC POLYMERIC MATERIAL - The invention provides a method for imparting antiviral properties to a hydrophilic polymeric material comprising preparing a hydrophilic polymeric slurry, dispersing an ionic copper powder mixture containing cuprous oxide and cupric oxide in said slurry and then extruding or molding said slurry to form a hydrophilic polymeric material, wherein water-insoluble particles that release both Cu | 05-22-2014 |
| 20140141074 | CONCENTRATED THERAPEUTIC PHOSPHOLIPID COMPOSITIONS - The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition. | 05-22-2014 |
| 20140154308 | Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture - Microparticle formulations are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions. | 06-05-2014 |
| 20140154309 | SOLID GANAXOLONE COMPOSITIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 06-05-2014 |
| 20140154310 | PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACIDS - The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. | 06-05-2014 |
| 20140161878 | MULTI-NUTRIENT SUPPLEMENT AND USES THEREOF - Various embodiments of the invention relate to compositions comprising vitamins, minerals and trace elements, antioxidants, amino acids, probiotics, and other components and methods for using such compositions to treat or prevent diseases associated with oxidative stress, including cardiovascular disease. | 06-12-2014 |
| 20140170211 | COMPOSITIONS AND METHODS FOR TREATING TRAUMATIC BRAIN INJURY - The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within. | 06-19-2014 |
| 20140170212 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 06-19-2014 |
| 20140170213 | CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE - Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects. | 06-19-2014 |
| 20140170214 | SUPRAMOLECULAR CAPSULES - Provided is a capsule having a shell of material that is a supramolecular cross-linked network. The network is formed from a host-guest complexation of cucurbituril (the host) and one or more building blocks comprising suitable guest functionality. The complex non-covalently crosslinks the building block and/or non-covalently links the building block to another building block thereby forming the supramolecular cross-linked network. The capsules are obtained or obtainable by the complexation of a composition comprising cucurbituril and one or more building blocks having suitable cucurbituril guest functionality thereby to form a supramolecular cross-linked network. | 06-19-2014 |
| 20140178466 | Steroidal Compositions - Provided herein are steroid containing composition suitable for providing therapeutically effective amount of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein. | 06-26-2014 |
| 20140186436 | ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES - The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can be used in methods designed to lower blood alcohol levels in vivo, and/or to break down the toxic byproducts of alcohol metabolism. Consequently these nanocomplexes can be used to treat a variety of conditions resulting from the consumption of alcohol, including for example, acute alcohol intoxication. | 07-03-2014 |
| 20140193487 | COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING - Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery. | 07-10-2014 |
| 20140193488 | In Situ Antigen-Generating Cancer Vaccine - The invention provides compositions and methods for utilizing scaffolds in cancer vaccines. | 07-10-2014 |
| 20140193489 | Dopamine Nanocapsules and Uses Thereof - The present invention provides a sonochemical irradiation-based method for the preparation of polydopamine (PDA) nanocapsules having reduced wall thickness and uniform size distribution, which may further comprise at least one payload; nanocapsules obtained by this method; and compositions thereof. Such compositions may be formulated for different purposes, e.g., as pharmaceutical compositions for various therapeutic or diagnostic purposes. | 07-10-2014 |
| 20140199380 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALGAE ADAPTED TO INCREASE THE EFFICACY OF AN ENZYMATIC INHIBITOR - A pharmaceutical composition comprising at least one algae, wherein said algae is adapted to increase the efficacy of an enzymatic inhibitor. | 07-17-2014 |
| 20140199381 | CORE-SHELL MICROSPHERES - The specification describes a substance comprising a plurality of microparticles. The microparticles comprise a core comprising a first polymer and a shell surrounding said core and comprising the first polymer and a second polymer, wherein the second polymer is less rapidly degradable than the first polymer. A process for making the microparticles and uses of the microparticles are also described. | 07-17-2014 |
| 20140199382 | STABLE PHARMACEUTICAL COMPOSITIONS OF AN S1P RECEPTOR AGONIST - The present invention relates to a stable pharmaceutical composition comprising an S1P receptor agonist and one or more pharmaceutically acceptable excipients, wherein the composition is free of a sugar alcohol. It also relates to method of preparing such compositions and using those compositions in the treatment of multiple sclerosis. | 07-17-2014 |
| 20140199384 | Facile Route to the Synthesis of Resorcinarene Nanocapsules - Described is a direct method for the fabrication of resorcinarene nanocapsules by photopolymerization of compounds of formula (I), such as resorcinarene tetraalkene tetrathiol (RTATT), in the absence of any template or preorganization. Further, by varying the polymerization media, a variety of other polymeric architectures like lattices, fibrous networks, and nanoparticles were obtained. The morphology and structure were characterized by transmission electron microscopy, energy dispersive spectroscopy, scanning electron microscopy, dynamic light scattering, infrared and nuclear magnetic resonance spectroscopy. These morphologically distinct resorcinarene polymeric architectures contain residual thiol and ene functional groups offering potential functionalization opportunities. | 07-17-2014 |
| 20140199385 | BIODEGRADABLE, SEMI-CRYSTALLINE, PHASE SEPARATED, THERMOPLASTIC MULTI BLOCK COPOLYMERS FOR CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS - This invention is directed to a biodegradable, semi-crystalline, phase separated thermoplastic multi-block copolymer, a process for preparing said multi-block copolymer, a composition for the delivery of at least one biological active compound, and to a method for delivering a biologically active compound to a subject in need thereof. | 07-17-2014 |
| 20140212482 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 07-31-2014 |
| 20140212483 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. | 07-31-2014 |
| 20140220118 | SOLID FORMULATIONS OF OSPEMIFENE - This invention relates to a solid drug formulation comprising granulates containing• a therapeutically active compound of the formula (I) | 08-07-2014 |
| 20140234405 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT - To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes. | 08-21-2014 |
| 20140234406 | NOVEL NANOPARTICULATE SUSPENSION FOR INCORPORATING FAT-SOLUBLE VITAMINS IN THE TREATMENT OF HAIR THINNING and HAIR LOSS - The present invention provides novel compositions comprising a nutritional supplement containing vitamin D-3 (cholecalciferol) and other supporting nutrients (i.e., fat-soluble vitamins A and E) to be administered orally via capsules to human subjects for the prophylaxis and mitigation of hair thinning and hair loss in both men and women. Colloidal silicon dioxide functions to form a nanoparticulate suspension and acts as a viscosifier to thicken the oil(s) used in the capsule filling operation. The colloidal silica contains silicon which acts as a nutrient to help strengthen existing hair, and also functions as a microencapsulation agent, which can incorporate vitamins A and E into its porous structure by sonication. | 08-21-2014 |
| 20140234407 | Method for Increasing Lactose Tolerance in Mammals Exhibiting Lactose Intolerance - The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely. | 08-21-2014 |
| 20140234408 | BEVERAGE COMPOSITIONS AND OTHER FORMULATIONS FOR TREATING ALLERGIES AND METHODS FOR MAKING THE SAME - A composition for preventing and/or alleviating an allergy related condition and methods of making such compositions are disclosed herein. A composition in accordance with a particular embodiment can include honey having pollen derived from a known plant species and/or from a known geographic location. The composition can also include a herbal and/or vitamin supplement, wherein the supplement has an anti-inflammatory property. The composition can be in liquid form, such as suitable for drinking, or in a powdered form suitable for reconstitution in liquid. | 08-21-2014 |
| 20140242158 | Granular Pharmaceutical Composition - The present invention relates to a granular pharmaceutical composition obtained by coating a nucleus with: (1) a layer containing a material having a damp-proofing function, and (2) a drug layer containing linaclotide, a pharmaceutically acceptable salt, or a hydrate thereof, and (3) a layer containing a material having a damp-proofing function. Also, the present invention relates to a method for manufacturing the granular pharmaceutical composition obtained by coating the nucleus with (1) the layer containing the material having a damp-proofing function, (2) the drug layer containing the linaclotide, the pharmaceutically acceptable salt, or the hydrate thereof, and (3) the layer containing the material having a damp-proofing function. | 08-28-2014 |
| 20140248340 | COATED CONTROLLED RELEASE ACTIVE AGENT CARRIERS - The present invention relates to carriers for the controlled release of active agents, comprising a core, comprising surface reacted natural or synthetic calcium carbonate, and at least one active agent, wherein said at least one active agent is associated with said natural or synthetic surface-reacted calcium carbonate, and wherein said surface-reacted natural or synthetic calcium carbonate is a reaction product of natural or synthetic calcium carbonate with carbon dioxide and one or more acids, wherein the carbon dioxide is formed in situ by the acid treatment and/or is supplied from an external source, and a coating encapsulating the core. It furthermore relates to the preparation of loaded carriers, as well as their use in different applications. | 09-04-2014 |
| 20140255476 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING INFECTIONS - Compositions, devices, and methods for treating infections. | 09-11-2014 |
| 20140255477 | Compositions and Methods for Delivery of High-Affinity Oxygen Binding Agents to Tumors - While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body. | 09-11-2014 |
| 20140255478 | Hair styling compositions - Hair styling compositions include at least one volatile compound and a hair fixative co-polymer, in which the hair fixative co-polymer includes at least one first monomer having an acid containing group and at least one second monomer having a hydrophobic group. The hair styling compositions provide extended release of volatile compounds, such as fragrances. | 09-11-2014 |
| 20140271830 | COMPOSITION AND METHOD FOR GRAY HAIR TREATMENT - A treatment for gray hair is described. The treatment can include a composition for treating gray hair with an active mixture including black trap molasses and vinegar. A standard ratio of vinegar to blackstrap molasses can be at least 1:10. The treatment can also include providing an ingestible hair treatment product including the active mixture and administering a quantity of the hair treatment product to deliver an effective amount of the active mixture. | 09-18-2014 |
| 20140271831 | RACECADOTRIL LIQUID COMPOSITIONS - A liquid composition comprising racecadotril and cyclodextrin. | 09-18-2014 |
| 20140271832 | RACECADOTRIL LIPID COMPOSITIONS - A composition comprising racecadotril, at least one surfactant and a lipid. | 09-18-2014 |
| 20140271833 | INJECTION-MOLDED DOSAGE FORM - An injection-molded shell of a dosage form of good quality is producible by a) providing a composition comprising i) from 25 to 90 weight percent of ethylcellulose, ii) from 7.5 to 60 weight percent of a polysaccharide or polysaccharide derivative being different from ethylcellulose, and iii) from 2.5 to 50 weight percent of at least one component being different from polysaccharides and polysaccharide derivatives, based on the total weight of the composition, with the proviso that the composition comprises zero or not more than 10 weight percent of gelatin and zero or not more than 10 weight percent of a polymer comprising homo- or copolymerized acrylic acid, homo- or copolymerized methacrylic acid, a homo- or copolymerized acrylate or a homo- or copolymerized methacrylate, and b) subjecting the composition to shearing and heat to plasticize the composition and injection-molding the plasticized composition into a three-dimensional shell of a dosage form. | 09-18-2014 |
| 20140287032 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase - The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid. | 09-25-2014 |
| 20140287033 | LIPID THERAPY - A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation. | 09-25-2014 |
| 20140294944 | MICROENCAPSULATION OF OXYGEN LIBERATING REACTANTS - There is provided a composition for the delivery of oxygen having microencapsulated peroxide and microencapsulated catalyst that liberate oxygen upon sufficient contact with each. The components may be stored separately or together until use. Upon mixing, oxygen is liberated. The composition can be used for wound healing or for cosmetic applications to deliver oxygen to the skin to help skin elasticity and retard the effects of aging. | 10-02-2014 |
| 20140294945 | METHODS AND DEVICES FOR FORMING TREATMENT AGENT CARRIERS - A method is described including passing a solution having a biodegradable polymer, a solvent and a treatment agent through an electrocharged nozzle to form particles encapsulating the treatment agent. The particles emitted from the electrocharged nozzle may be exposed to a charge opposite that of the nozzle. The particles may be deposited in a collection assembly comprising a liquid phase. A further method including combining a biodegradable polymer, a solvent and a treatment agent to form a solution, electrodepositing the solution in a particle form wherein the particles encapsulate the treatment agent in a collection assembly comprising a liquid phase and mixing the particles with a bioerodable material capable of forming a gel is described. An apparatus having an electrocharged nozzle, a grounded electrode having an opposite charge to that of the nozzle and a collection assembly comprising a liquid phase is further disclosed. | 10-02-2014 |
| 20140294946 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 10-02-2014 |
| 20140294947 | TAMPER RESISTANT IMMEDIATE RELEASE FORMULATIONS - Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising a gelling agent; (ii) an optional barrier layer encompassing the core; (iii) an active layer comprising a drug susceptible to abuse encompassing the core or barrier layer; and (iv) an optional controlled release excipient; wherein the dosage form provides an immediate or controlled release; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration. | 10-02-2014 |
| 20140302125 | Methods for treating cardiovascular disorders - There is provided a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more calcium channel blocker, angiotensin II receptor blocker or angiotensin converting enzyme inhibitor along with one or more rate controlling excipient. | 10-09-2014 |
| 20140302126 | Rhein or diacerein compositions - The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions. | 10-09-2014 |
| 20140302127 | Novel formulation of metaxalone - The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments. | 10-09-2014 |
| 20140302128 | Biological oil composition, formulations comprising the oil composition, and use thereof to prevent or treat cardiovascular disease - This invention relates to a biological oil composition, preferably obtained from a copepod, most preferably the copepod | 10-09-2014 |
| 20140302129 | HUMAN LUBRICATION GEL - Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site. | 10-09-2014 |
| 20140302130 | SILICA-MATRIX FORMING COMPOSITIONS, MATERIALS FORMED THEREFROM, AND METHODS OF USING THE SAME - The present invention provides compositions for encapsulation of biomaterials in a silica-matrix. The present invention also provides methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials. In one embodiment, the present invention provides a method of encapsulating mammalian cells in a silica-matrix while maintaining metabolic activity. In another embodiment, the present invention provides a method of purifying cancer cells using a silica-matrix. | 10-09-2014 |
| 20140308343 | METHOD FOR PREPARING NANOPARTICLES BASED ON FUNCTIONAL AMPHIPHILIC MOLECULES OR MACROMOLECULES, AND THE USE THEREOF - The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents. | 10-16-2014 |
| 20140308344 | METHODS FOR TREATING MULTIPLE MYELOMA WITH 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE AFTER STEM CELL TRANSPLANTATION - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 10-16-2014 |
| 20140308345 | KRILL OIL AND REACTED ASTAXANTHIN COMPOSITION AND ASSOCIATED METHOD - A method of enhancing cardiovascular health includes administering a therapeutic amount of a composition comprising krill oil reacted with astaxanthin. A medicine delivery system for the method and composition includes an inner capsule containing carotenoids and an outer capsule in which the inner capsule is contained within the outer capsule and the outer capsule containing a therapeutically effective amount of krill oil. In one example, the carotenoids comprise at least S, S′-astaxanthin derived from | 10-16-2014 |
| 20140314839 | CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF - Controlled-release formulations of carboxy-terminal C5a analogs (such as sustained-release formulations of the analogs), and their use in methods for treating and preventing an infection or a disease such as cancer, for directly killing microorganisms, for vaccine preparation, for inducing an immune response and for targeting antigen-presenting cells and other cells bearing a C5a receptor, are provided. | 10-23-2014 |
| 20140322311 | CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 10-30-2014 |
| 20140322312 | PROTON PUMP-INHIBITOR-CONTAINING CAPSULES WHICH COMPRISE SUBUNITS DIFFERENTLY STRUCTURED FOR A DELAYED RELEASE OF THE ACTIVE INGREDIENT - An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active; a population of a basic substance; a population of enteric coated pharmaceutical active; and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma. | 10-30-2014 |
| 20140328906 | Methods of Treating Impaired Glucose Metabolism via Administration of Algal Biomass - The invention is directed to methods of using | 11-06-2014 |
| 20140328907 | ENTRAPMENT OF BIOACTIVES IN SOL-GEL ALUMINA MATERIALS - Provided is a platform for entrapment within alumina sol-gel carriers of labile biologically active materials such as proteins, therapeutic enzymes, enzymes of industrial relevance, antigens, and small molecules for achieving successful and efficient protective storage, protection from harsh environmental conditions such as heat, pH and chemicals, delivery to site and subsequent treatment and/or vaccination against diseases against which the active agents are targeted. | 11-06-2014 |
| 20140335166 | Methods of Making and Using Nano Scale Particles - A method for preparing a phospholipid delivery system encapsulating one or more bio-affecting compounds, includes the steps of solubilizing a heterogeneous phospholipid mixture into an organic solvent to form a concentrated formulation of phospholipids, in which the phospholipids include a charged phospholipid species and mixing the concentrated formulation with an aqueous solution having at least one bio-affecting compound. A method of using a phospholipid delivery system encapsulating at least one bio-affecting compound for the administration to an individual in need thereof is also disclosed. | 11-13-2014 |
| 20140335167 | Consumer Products Comprising Silane-Modified Oils - A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The silane-modified oil is substantially stripped of substantially stripped of reagents prior to formulating into the consumer products, such that the silane-modified oil comprises less than about 10%, preferably less than about 5%, preferably less than about 1%, preferably less than about 0.1%, by weight of said silane-modified oil, of residual reagent comprising silicon. | 11-13-2014 |
| 20140335168 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 11-13-2014 |
| 20140341981 | EMULSION STABILIZATION VIA SILICILIC ACID COMPLEXATION - Disclosed are methods of preparing stable O/W emulsions by silicic acid complexation of micron-sized oil droplets, and stable emulsions prepared by silicic acid complexation. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature. | 11-20-2014 |
| 20140341982 | Vaccination With Immuno-Isolated Cells Producing An Immunomodulator - The present invention relates to immuno-protected encapsulated cells producing an immunomodulator, for example GM-CSF (granulocyte-macrophage colony stimulating factor). The cells of the invention are particularly well adapted for providing an active adjuvant or immunomodulator, for example in the context of immunisation in humans and animals. These cells can be used for vaccination where they provide the immunomodulator in an active form, in a continuous, non-immunogenic manner in the immediate vicinity of the vaccine antigen(s). The invention also relates to a vaccine composition comprising immuno-protected encapsulated cells producing an immunomodulator and an antigenic component. The invention also relates to a kit comprising a cell as described and an antigenic component. The strategy of the invention is perfectly suited for both cancer immunotherapy and vaccination against infectious agents. | 11-20-2014 |
| 20140341983 | SMART.TM. SOLID ORAL DOSAGE FORMS - Solid Oral Dosage Forms (SODFs) comprising Self Monitoring and Reporting Therapeutics (SMART™) adherence technology are provided which require no or minimal modification of clinical trial materials (CTMs) or marketed drug while providing tamper resistant (literally foolproof) measurement of adherence that is highly accurate and without altering the chemical, manufacturing, and controls (CMC) of the CTM or marketed drug. | 11-20-2014 |
| 20140341984 | TAMPER RESISTANT PHARMACEUTICAL FORMULATIONS - Disclosed in certain embodiments is an oral dosage form comprising a plurality of particles, each particle comprising a compressed core comprising: (i) an active agent susceptible to abuse and (ii) a gelling agent; wherein the plurality of particles contains a therapeutically or prophylactically effective amount of the active agent; and wherein the viscosity of the dosage form mixed with from about 0.5 to about 10 ml of an aqueous liquid is unsuitable for parenteral or nasal administration. | 11-20-2014 |
| 20140348909 | PHARMACEUTICAL COMPOSITIONS OF LURASIDONE - The present invention relates to pharmaceutical compositions of lurasidone or salts thereof. In particular, the invention relates to pharmaceutical compositions of lurasidone or salts thereof with one or more water-insoluble pharmaceutical excipients. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of schizophrenia, bipolar disorders or senile dementia. | 11-27-2014 |
| 20140348910 | Topical Formulations Including Lipid Microcapsule Delivery Vehicles and Their Uses - The present invention relates to topical formulations that include lipid microcapsules formed from tocopherol, tocotrienol, or mixtures thereof; a stabilizer/surfactant component; and an aqueous component. The lipid microcapsules may be formed without the use of steroids, preservatives, initiators and/or oils. The topical formulations are capable of delivering transdermal active agent(s) such as vitamin D through the skin and into the bloodstream without the use of skin penetration enhancers. In certain embodiments, the topical formulations also able to deliver topical active agent(s) such as sun-protecting agents to the surface of the skin where they remain, while simultaneously delivering the transdermal active agent(s) through the skin and into the bloodstream. | 11-27-2014 |
| 20140348911 | SPRAY FORMULATION OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CHRONIC WOUNDS - The present Invention describes therapeutic and medical applications of Mesenchymal Stem Cells, by means of fine mist spraying application system. The mesenchymal stem cells used in the fine mist spray application system are in suspension and may optionally be nanoencapsulated or not. | 11-27-2014 |
| 20140356420 | MICRO-PARTICLE COMPRISING A PROTEIN EXTRACT FROM SWEET POTATO FOR EXTENDING SATIETY AND CONTROLLING BLOOD GLUCOSE AND LIPID LEVELS - The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein the protein extract from sweet potato contains trypsin inhibitor and glycoprotein. The micro-particle comprising a protein extract from sweet potato can effectively extend satiety, control blood glucose and lipid levels and increase metabolism effectively. | 12-04-2014 |
| 20140356421 | Antibody-Conjugated Double-Emulsion Nanocapsule and Preparation Methods Thereof - An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody. | 12-04-2014 |
| 20140356422 | STABLE PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION COMPRISING LEVOCETIRIZINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MONTELUKAST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation according to the present invention comprises an organic acid as a stabilizing agent, which can effectively inhibit the production of levocetirizine and montelukast related substances, and thus, show good stability. | 12-04-2014 |
| 20140363501 | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury - An anti-oxidative | 12-11-2014 |
| 20140363502 | Resveratrol-Containing Compositions and Methods of Use for Treatment of Macular Degeneration - The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to a recipient, increases the concentration or activity of a survival/longevity gene product and/or decreases the concentration or activity of a gene product that induces or causes cellular damage. Most preferably, the resveratrol-stabilizing composition will comprise the chelator phytic acid (inositol hexaphosphate; IP6), hyaluronic acid, and vitamin D. The invention further pertains to the use of such compositions in the treatment or prevention of cancer, cardiovascular disease, diseases associated with aging, and other conditions and illnesses. | 12-11-2014 |
| 20140377341 | CELL LINES AND THEIR USE IN ENCAPSULATED CELL BIODELIVERY - The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide. | 12-25-2014 |
| 20140377342 | WAFER AND CAPSULE FORMULATIONS WITH ENHANCED DISSOLUTION RATES FOR FENOFIBRATE - The objective of this invention is to develop a novel wafer and capsule formulations using fenofibrate which is difficult to dissolve and control its release rate in vitro. | 12-25-2014 |
| 20150010620 | Bulk Enteric Capsule Shells - The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with bulk enteric properties. The present disclosure also relates, in part, to aqueous dispersions suitable for the implementation of said manufacturing process, and to enteric capsule shells and hard capsules obtained therewith. | 01-08-2015 |
| 20150017236 | PHARMACEUTICAL COMPOSITIONS OF THYROID HORMONE - Provided herein are methods of stabilizing thyroid hormone, preventing a thyroid hormone from being oxidized, producing a formulation of thyroid hormone having a uniform potency, and reducing the exposure of a thyroid hormone to oxygen, light, moisture, or high temperature. Such methods comprise coating said thyroid hormone to provide a solid form comprising thyroid hormone coated with a coating material. Also provided are pharmaceutical compositions comprising a solid form of a thyroid hormone, wherein said solid form comprises thyroid hormone coated with a coating material. The invention also provides pharmaceutical compositions produced by the methods. Unit dosage forms and batches comprising such pharmaceutical compositions are also provided. | 01-15-2015 |
| 20150017237 | DOSAGE FORM COMPRISING LOPINAVIR AND RITONAVIR - The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms containing the above pharmaceutical active agents. | 01-15-2015 |
| 20150024041 | Health Supplement using Guarana Extract - The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, Methyl B12 or B12, Niacin, Guarana, Dimethylaminoethanol, Acetyl-L-carnitine or ALCAR, | 01-22-2015 |
| 20150030673 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETH- YL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE - Provided herein is a hydrogen chloride salt of 1-(3-/t?r/-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea, crystalline forms of 1-(3-½̂butyl-1̂-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride, processes for the preparation of said crystalline forms, pharmaceutical compositions containing a crystalline form of 1-(3-r | 01-29-2015 |
| 20150044281 | METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER DEMYELINATING DISORDERS - This invention provides compositions and methods for preventing multiple sclerosis or other demyelinating disorders, inhibiting multiple sclerosis or other demyelinating disorders, or prolonging remission from MS or other demyelinating disorders comprising administering to a subject a microparticle comprising a biodegradable material comprising at least one IL-10 coding sequence. | 02-12-2015 |
| 20150050333 | PHARMACEUTICAL COMPOSITION COMPRISING OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT - Provided is a pharmaceutical composition having a single dosage form including a compartment including olmesartan medoxomil; and a compartment including rosuvastatin or its salt, wherein said compartments are formulated in a separate form. In the pharmaceutical composition of the present invention, olmesartan medoxomil and rosuvastatin or its salt are formulated into a combination dosage form having separate compartments, thereby being able to solve the absorption-inhibition problem originated from drug interaction. In addition, the use of a certain disintegrant(s) makes it possible to obtain a combination formulation bioequivalent to the single formulation of each of drugs. | 02-19-2015 |
| 20150056274 | COMPOSITIONS, METHODS AND KITS FOR REDUCING LIPID LEVELS - Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol. | 02-26-2015 |
| 20150064241 | Delivery of Functionalized Particles - A device includes a capsule sized to pass through a lumen of a gastrointestinal tract, a plurality of functionalized particles disposed within the capsule, one or more tissue penetrating members configured to puncture a wall of the lumen of the intestinal tract; and an actuator having a first configuration and a second configuration. The actuator is configured to retain the plurality of functionalized particles within the capsule in the first configuration. The actuator is further configured to advance the plurality of functionalized particles from the capsule into a wall of the lumen of the gastrointestinal tract via the one or more tissue penetrating members by the actuator transitioning from the first configuration to the second configuration. Systems including the device and methods of delivering functionalized particles to the body are also provided. | 03-05-2015 |
| 20150064242 | TRIALKYL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. | 03-05-2015 |
| 20150064243 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ADMININISTRATION OF HYDROPHOBIC DRUGS - Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided. | 03-05-2015 |
| 20150064244 | KONJAC FORMULATION AND METHOD FOR PREPARING THE SAME - A konjac formulation in the form of a capsule, including between 85 and 95 parts by weight of konjac gum, between 5 and 10 parts by weight of black rice, between 0.5 and 2 parts by weight of biological Fe, and between 0.5 and 2 parts by weight of vitamin. | 03-05-2015 |
| 20150071993 | Compositions and Methods for Improving Sleep Using A Nutraceutical Formulation - Provided are supplemental compositions for a nutraceutical formulation and methods for administering the same to a user for inducing or maintaining sleep as well as for alleviating pain to improve sleep using a formulation of ingredients comprising of extract of ashwagandha, extract of lavender, extract of valerian, extract of hops, melatonin, magnesium, vitamin B12, and zinc, and/or devil's claw, bromelain and boswellia. | 03-12-2015 |
| 20150079162 | CERIA NANOCOMPLEX, PHARMACEUTICAL COMPOSITION COMPRISING SAID CERIA NANOCOMPLEX, AND METHOD FOR PREPARING SAME - The present invention relates to ceria nanocomposite, pharmaceutical composition comprising the ceria nanocomposite, and method for preparing same. More particularly, the present invention is directed to a ceria nanocomposite comprising a ceria nanoparticle, wherein the ceria nanoparticle is encapsulated with a surfactant and the surfactant is encapsulated with polyethylene glycol-phospholipid, pharmaceutical composition for preventing or treating ischemic stroke comprising thereof and method for preparing the same. | 03-19-2015 |
| 20150086621 | DIETARY FIBER COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASE - Dietary fibre compositions composed of 48-90% w/w glucomannan, 5-20% w/w xanthan gum and 5-30% w/w alginate in combination with metformin, sitagliptin or a mixture thereof for the treatment of metabolic disease are disclosed. | 03-26-2015 |
| 20150086622 | GROWTH ENHANCEMENT OF INFANTS - The present invention relates to compositions and methods for enhancing the growth of infants. Particularly, the present invention discloses the use of insulin for promoting the growth of low birth weight infants, including preterm infants and small for gestational age (SGA) infants over the expected rate. | 03-26-2015 |
| 20150093436 | MODIFIED RELEASE DOSAGE FORMS OF SKELETAL MUSCLE RELAXANTS - A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period. | 04-02-2015 |
| 20150104502 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 04-16-2015 |
| 20150104503 | COMPLEXES AND COMPOSITIONS CONTAINING CURCUMIN - A complex is provided, including a phospholipid and curcumin, wherein the phospholipid is sourced from a marine oil. | 04-16-2015 |
| 20150110863 | SULFORAPHANE-DERIVED COMPOUNDS, PRODUCTION METHOD THEREOF AND THE MEDICAL, FOOD AND COSMETIC USE OF SAME - The present invention relates to a new series of compounds having general formula (I) and the optical isomer or enantiomer forms thereof, which belong to the family of sulforaphane derivatives. The invention also relates to the production method thereof. The invention further relates to the multiple medical (pharmaceutical, homeopathic and phytotherapeutic), food, cosmetic and dietary uses of said series of compounds, especially the use thereof in the prevention and/or treatment of diseases and any type of illness or damage associated with an oxidative process or which, although not involved in said process, are mediated by the Nrf2 transcription factor, such as, for example, cancer. The compounds can be used alone or, alternatively, encapsulated in cyclodextrins. | 04-23-2015 |
| 20150110864 | NOVEL ANTITUMOR AGENT COMPRISING COMBINATION OF THREE AGENTS - A primary object of the present invention is to provide a novel combination therapy that exhibits a notable antitumor effect. | 04-23-2015 |
| 20150110866 | COMPLEXES AND COMPOSITIONS CONTAINING CURCUMIN - A complex is provided, including a phospholipid and curcumin, wherein some or all of the phospholipid is a marine phospholipid. In addition, a composition is provided including a complex with a phospholipid and curcumin, wherein some or all of the phospholipid in the complex is a marine phospholipid. In addition, a method is provided of preparing a complex or composition including the steps of:
| 04-23-2015 |
| 20150118292 | COMPOSITIONS AND METHODS FOR TREATMENT OF HAIR LOSS - The present invention is directed to compositions and methods suitable for the treatment of alopecia by topical application include minoxidil sulfate, finasteride, and 17α-estradiol. The combination is characterized by low alcohol content to minimize skin irritation and may be enhanced with the addition of vitamins, minerals, and peptides. The topical use of this combination leads to a lower overall risk of side effects than orally administered drugs. | 04-30-2015 |
| 20150118293 | NOVEL DELIVERY SYSTEM FOR ANTICANCER DRUG BASED ON SHORT-CHAIN-LENGTH POLYHYDROXYALKANOATE NANOPARTICLES - The invention relates to the fabrication of novel and improved delivery system comprising of short-chain-length polyhydroxyalkanoates (scl-PHA) nanoparticles having anticancer drug ellipticine (EPT) encapsulated therein for oral administration. The scl-PHA is synthesized by indigenous bacterial isolate | 04-30-2015 |
| 20150125520 | LIPID NANOCAPSULES COMPRISING A RETINOID, NANODISPERSION AND COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN DERMATOLOGY - Lipid nanocapsules are described that include at least one irritating active ingredient, and more specifically a retinoid in solubilized form. Also described, are nanodispersions and pharmaceutical compositions including the same and methods of producing the same. The use of the pharmaceutical compositions in the treatment of dermatological pathologies is also described. | 05-07-2015 |
| 20150132371 | USE OF TOMATO EXTRACT AS ANTIHYPERTENSIVE AGENT AND PROCESS FOR MAKING WATER SOLUBLE SUGAR FREE TOMATO EXTRACT - Provided herein is technology relating to tomato extracts and particularly, but not exclusively to preparing and using tomato extracts as an anti-hypertensive agent to modulate blood pressure. | 05-14-2015 |
| 20150132372 | AQUEOUS DISPERSIONS OF CONTROLLED RELEASE POLYMERS AND SHELLS AND CAPSULES THEREOF - The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells and capsules with a functional polymer dispersion. The present disclosure relates to aqueous compositions for use in the manufacture of capsule shells endowed with controlled release properties. The present disclosure also relates to aqueous compositions for use in the manufacture of capsule shells and capsules endowed with moisture barrier properties. The present disclosure also relates to methods of manufacturing the capsule shell and capsules, and to capsule shells and capsules obtained therewith. | 05-14-2015 |
| 20150132373 | LYCOPENE AND RESVERATROL DIETARY SUPPLEMENT - A dietary supplement is disclosed comprising lycopene and resveratrol in a range of ratio of lycopene:resveratrol from 1:10 to 10:1. Preferably, the ratio is 1:2 to 1:4. Lycopene is preferably of ≧95% purity and resveratrol is of ≧98% purity. Both lycopene and resveratrol may preferably comprise of nano-sized particles in crystal powder to optimize oral intake in the form of capsule or tablet. In small dosage, it should preferably include a minimum of 5 mg of lycopene and 10 mg of resveratrol. Various range of ratios of lycopene:resveratrol are provided for specific therapeutic purposes including 1:4 for symptomatic relief of arthritis, 1:2 for inhibiting melanoma or carcinoma malignancy, and 1:3 for inhibiting hyperlipoidemia. Generally, our dietary supplement composition may be used as an agent for anti-ageing, anti-oxidative, inhibiting cardiovascular diseases, relieving menopause symptoms and remission of post-operative cancer patients. | 05-14-2015 |
| 20150140083 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 05-21-2015 |
| 20150147388 | Materials and Methods for Modulating immune Responses - The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses. | 05-28-2015 |
| 20150147389 | NOVEL ANTIOXIDANT FORMULATIONS - An antioxidant composition comprises one or more amino acids; a genistein alternative selected from the group consisting of genistein, aglycon genistine, hormone receptive modulators, phosphordiesterase (PDE) inhibitors of types 1, 2, 3 and 4, anti-neoplastic tyrosine kinase inhibitors, and combinations thereof; and an icariin alternative selected from the group consisting of icarosides 1 or 2, PDE-4 inhibitors, PDE-5 inhibitors, derivatives of the epimedium species including icarrocides I and II, and combinations thereof. | 05-28-2015 |
| 20150147390 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 05-28-2015 |
| 20150297537 | Compositions for the Treatment of CNS-Related Conditions - The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine. | 10-22-2015 |
| 20150297555 | COMBINATION THERAPEUTICS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER DISEASES - Embodiments of the present invention are directed to the administration of bryostatins and bryostatins and retinoids for the treatment of disease responsive to increases in alpha secretase activity. Inventions of the present application are directed to the treatment of neuro-degenerative diseases such as Hutchinson Disease, Parkinson's disease, Down's syndrome and Alzheimer's disease and virus latency diseases such as HIV and Herpes, cancers such as prostate, melanomas, lymphomas and renal cancers, esophageal and opthalmic diseases such as glaucoma. | 10-22-2015 |
| 20150313871 | Methods of Treating Portal Hypertension - The present invention provides methods for treating or preventing portal hypertension comprising administering to a patient in need of such treatment or prevention at least one Rev-erb modulating agent (REMA) in an amount effective to treat or prevent said portal hypertension. The REMA can be SR6452 or a related compound, such as SR9009 or SR9011. The amount of the REMA administered can comprises a quantity sufficient to modulate Rev-erbα expression, activity, and/or subcellular location and/or to inhibit or reverse hepatic stellate cell (HSC) activation and contractility. | 11-05-2015 |
| 20150313892 | PHARMACEUTICAL COMPOSITIONS FOR TREATING PAIN ASSOCIATED WITH DYSMENORRHEA - Pain associated with primary and secondary dysmenorrhea is relieved in a human suffering there from by administering to the human a pain relieving amount of a synergistically acting sub-therapeutic combination of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, magnesium, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, tramadol or its analog such as recemic tramadol or an analogously acting molecular entity or pharmaceutically acceptable salt thereof, and an anticonvulsant and/or a tricyclic anti-depressant or pharmaceutically acceptable salt thereof, and optionally in sustained release dosage form. | 11-05-2015 |
| 20150320711 | Capsules Containing High Doses of Levodopa for Pulmonary Use - The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide. | 11-12-2015 |
| 20150335607 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE - In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. | 11-26-2015 |
| 20150343019 | RECOMBINANT LUBRICIN MOLECULES AND USES THEREOF - Recombinant lubricin molecules and uses thereof. Novel recombinant lubricin molecules and their uses as lubricants, anti-adhesive agents and/or intra-articular supplements for, e.g., synovial joints, meniscus, tendon, peritoneum, pericardium and pleura, are provided. | 12-03-2015 |
| 20150352052 | 2,2',6,6'-TETRAISOPROPYL-4,4'-2-BIPHENOL SOFT CAPSULE AND METHOD FOR PREPARING SAME - Disclosed is a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2′,6,6′-tetraisopropyl-4,4′-biphenol, a solvent, and an antioxidant, among others. | 12-10-2015 |
| 20150359742 | COMPOSITIONS AND METHODS FOR ENHANCING THE TOPICAL APPLICATION OF A BENEFIT AGENT INCLUDING POWDER TO LIQUID PARTICLES AND A SECOND POWDER - A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes a polar liquid having a percent surface polarity of at least 24% and a shell comprising hydrophobic particles; and at least one second powder comprising a benefit agent. The powder can be used to topically administer the active ingredient to a human or animal. | 12-17-2015 |
| 20150366828 | MAGNESIUM COMPOSITIONS AND USES THEREOF FOR CANCERS - Compositions and methods that are useful for treating a subject suffering from one or more cancers are provided herein. Such compositions and methods can contain an effective amount of magnesium threonate to be used to support or improve the mental state of a subject. The composition and methods comprising magnesium threonate can also be used to support a cancer treatment. | 12-24-2015 |
| 20150374634 | Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use - The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed. | 12-31-2015 |
| 20160000728 | Multiparticulate L-Menthol Formulations and Related Methods - An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome. | 01-07-2016 |
| 20160000745 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES - The present invention relates to compositions and kits including a chemical uncoupler, such as tyrphostin 9 or precursor or a salt thereof, and compositions including a chemical uncoupler, such as tyrphostin 9 in combination with one or more therapeutic agents, for example, L-carnitine, which are useful, for example, in treating obesity, preventing weight gain, promoting weight loss/slimming, and/or treating or preventing the development of diabetes. | 01-07-2016 |
| 20160002173 | NANOPARTICULATE AND MACROPARTICULATE FORMULATIONS - The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described. | 01-07-2016 |
| 20160015629 | PHARMACEUTICAL COMPOSITION FOR PREPARING DRUG DELIVERY NANO/MICRO BUBBLES - The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure. | 01-21-2016 |
| 20160030493 | Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria - A composition is provided comprising extracts of at least grape seeds (GSE) and green tea. The extracts are preferably polyphenolic and preferably comprises probiotic bacteria. The use of extracts from green tea and grape seeds for the manufacture of a medicament against a neurodegenerative disease is also disclosed. | 02-04-2016 |
| 20160038425 | Non-Gelatin Enteric Soft Capsules - Described herein are pharmaceutical enteric soft capsules that do not contain gelatin as a film-forming polymer. In particular, compositions and methods for manufacturing enteric soft capsules comprising carrageenans as film forming polymers are disclosed. | 02-11-2016 |
| 20160045510 | METHODS OF IMPROVING MYOCARDIAL PERFORMANCE IN FONTAN PATIENTS USING UDENAFIL COMPOSITIONS - The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation. | 02-18-2016 |
| 20160051469 | BIODEGRADABLE COPOLYMERS, SYSTEMS INCLUDING THE COPOLYMERS, AND METHODS OF FORMING AND USING SAME - Therapeutic agent delivery systems, which include a thermally-sensitive copolymer and optionally a therapeutic agent, are disclosed. The copolymer is water soluble and biodegradable and, in accordance with exemplary embodiments, includes hydrophobic and hydrophilic portions. The systems may include supplemental compounds, such as polymeric nanoparticles, micelle compounds, or a combination thereof, to further provide sustained release of the therapeutic agent. | 02-25-2016 |
| 20160051470 | PHARMACEUTICAL COMPOSITIONS OF CAROTENOID - The present invention provides pharmaceutical compositions comprising a chylomicron and a carotenoid. The present invention also provides pharmaceutical compositions comprising a micelle and a carotenoid, suspended in an aqueous solution and suitable for intravenous administration. The bioavailability of the carotenoid of the pharmaceutical composition is higher relative to the bioavailability of free carotenoid. | 02-25-2016 |
| 20160051530 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES - Methods of treating, preventing and/or managing multiple myeloma are disclosed. Specific methods encompass the administration of an immunomodulatory compound, e.g., lenalidomide or pomalidomide with an anti-CS1 antibody, e.g., elotuzumab in patients who have received autologous stem cell transplantation. | 02-25-2016 |
| 20160058744 | AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE BY ADJUNCTIVE USE OF ANTIHYPERTENSIVE DRUGS - Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies. | 03-03-2016 |
| 20160058831 | LEARNING MOTIVATION IMPROVERS - The present invention aims to provide antidepressants which are free from the problem of side effects and are excellent in safety. The present invention also aims to provide learning motivation improvers which are useful for improvement of learning motivation and can be ingested continuously. | 03-03-2016 |
| 20160058856 | ANTI-TUMOR DNA VACCINE - The present invention provides a pharmaceutical composition for treating a tumor, which is a micelle encapsulating at least one tumor-associated antigen gene. The present invention also provides a method for treating a tumor, comprising administering a micelle encapsulating at least one tumor-associated antigen gene to a patient in need of such treatment. | 03-03-2016 |
| 20160074557 | COMPOSITIONS AND METHODS FOR MODIFYING IN VIVO CALCIFICATION OF HYDROGELS - Provided herein according to some embodiments of the invention are methods of inhibiting or preventing calcification of hydrogels. Such methods may include combining the hydrogel with a buffer solution having a pH lower than 7.4; forming hydrogel by crosslinking alginate in a solution comprising a bisphosphonate compound; and/or forming hydrogel by crosslinking polyanionic polymer with a polyvalent cation that is not Ca | 03-17-2016 |
| 20160089330 | DRY POWDER VANCOMYCIN COMPOSITIONS AND ASSOCIATED METHODS - Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided. | 03-31-2016 |
| 20160089339 | CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE - Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: ( | 03-31-2016 |
| 20160089383 | NUTRITIONAL SUPPLEMENTS - Provided are nutritional supplement preparations and methods for enhancing the outcome of a non-invasive tissue remodeling procedure, for providing the nutritional supplement to a subject, and for preparing such supplements. | 03-31-2016 |
| 20160106755 | PHARMACEUTICAL COMPOSITIONS - Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic. | 04-21-2016 |
| 20160128940 | DOCETAXEL NANO-POLYMER MICELLE LYOPHILIZED PREPARATION AND PREPARATION METHOD THEREOF - A docetaxel nano-polymer micelle lyophilized preparation is disclosed including methoxypolyethylene glycol-polylactic acid block copolymer carrier material and docetaxel, the docetaxel being is encapsulated in the carrier material. A mass ratio of the docetaxel to the carrier material is 0.01-0.15. The methoxypolyethylene glycol-polylactic acid block copolymer is formed by ring opening polymerization of D,L-lactide and methoxypolyethylene glycol. A mass ratio of the methoxypolyethylene glycol to the D,L-lactide is 1:0.55-0.65 or 1:0.73-0.89 or 1:0.91-0.99. The mass ratio of the docetaxel to the carrier is further optimized by adjusting a mass ratio of polyester to polyether in the methoxypolyethylene glycol polylactide block copolymer. The encapsulation efficiency of a docetaxel micelle prepared by the block copolymer after being re-dissolved by water can be greater than 90% at 12 hours. | 05-12-2016 |
| 20160136100 | MULTI-PHASE, MULTI-COMPARTMENT, CAPSULAR DELIVERY APPARATUS AND METHODS FOR USING SAME - A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber. | 05-19-2016 |
| 20160137638 | Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-YL)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate - Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. | 05-19-2016 |
| 20160144000 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 05-26-2016 |
| 20160145287 | Dendrimer Scaffolds for Pharmaceutical Use - This invention relates to certain dendrimer compounds. In particular, this invention relates to novel dendrimer compounds that can be elaborated to give increasingly large and complex compounds. These elaborated compounds can be attached to, or can encapsulate within, active agent(s) so as to beneficially modify the characteristics of that active agent. Alternatively, the elaborated compounds can themselves be beneficially modified into therapeutic agents by the attachment of inactive agents. | 05-26-2016 |
| 20160151243 | SOFT SHELL CAPSULE AND PROCESS FOR ITS MANUFACTURE | 06-02-2016 |
| 20160151306 | THERAPEUTIC ASTAXANTHIN AND PHOSPHOLIPID ROE EXTRACT COMPOSITION AND ASSOCIATED METHOD | 06-02-2016 |
| 20160151498 | Nanoparticle Compositions | 06-02-2016 |
| 20160158174 | Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients - Functional food ingredients for delivery to the gastrointestinal tract are delivered. Food products, nutraceuticals, and pharmaceuticals comprising the functional food ingredients, as well as methods for making the functional food ingredients, are also provided. The functional food ingredients may positively influence glucose metabolism and weight management. Generally, the ingredients include metabolites physically entrapped in a fermentation precursor, which is then encapsulated in an enteric coating for release in the large intestine of a human subject. In one approach, the ingredients include a polysaccharide matrix, short chain fatty acids physically entrapped in the polysaccharide matrix, and an enteric coating that encapsulates the combination of short chain fatty acids and polysaccharide matrix. | 06-09-2016 |
| 20160166505 | Methods And Compositions For Treatment Of Respiratory Tract Infections | 06-16-2016 |
| 20160175300 | PROCESS FOR PREPARING OXYCODONE DOCAGE FORM | 06-23-2016 |
| 20160175363 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | 06-23-2016 |
| 20160177268 | METHODS FOR GENERATING AUGMENTED STEM CELL-DERIVED BETA CELLS AND USES THEREOF | 06-23-2016 |
| 20160184260 | METHODS FOR PURIFYING TRANS-(-)-DELTA9-TETRAHYDROCANNABINOL AND TRANS-(+)-DELTA9-TETRAHYDROCANNABINOL - Methods for making trans-(−)-Δ | 06-30-2016 |
| 20160193151 | DOSAGE FORM INCORPORATING AN AMORPHOUS DRUG SOLID SOLUTION | 07-07-2016 |
| 20160199336 | CONTROLLED RELEASE FUMARATE ESTERS | 07-14-2016 |
| 20160375048 | SUSTAINED-RELEASE FORMULATIONS OF TOPIRAMATE - Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 12-29-2016 |
| 20170232029 | PHARMACEUTICAL ANTI-INFECTIVE COMPOSITION FOR INHALATION | 08-17-2017 |
| 20220133717 | RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to therapeutic uses of compositions comprising 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline in the treatment of human subjects suffering from Rheumatoid Arthritis. | 05-05-2022 |
